10593748

Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID:SSSPTA1626GMS

PASSWORD:
TERMINAL (ENTER 1, 2, 3, OR ?):2

* * * * * * * * * * Welcome to STN International * * * * * * * * * *

NEWS 1		Web Page for STN Seminar Schedule - N. America
NEWS 2	OCT 04	Precision of EMBASE searching enhanced with new chemical name field
NEWS 3	OCT 06	Increase your retrieval consistency with new formats or for Taiwanese application numbers in CA/CAplus.
NEWS 4	OCT 21	CA/CAplus kind code changes for Chinese patents increase consistency, save time
NEWS 5	OCT 22	New version of STN Viewer preserves custom highlighting of terms when patent documents are saved in .rtf format
NEWS 6	OCT 28	INPADOCDB/INPAFAMDB: Enhancements to the US national patent classification.
NEWS 7	NOV 03	New format for Korean patent application numbers in CA/CAplus increases consistency, saves time.
NEWS 8	NOV 04	Selected STN databases scheduled for removal on December 31, 2010
NEWS 9	NOV 18	PROUSDDR and SYNTHLINE Scheduled for Removal December 31, 2010 by Request of Prous Science
NEWS 10	NOV 22	Higher System Limits Increase the Power of STN Substance-Based Searching
NEWS 11	NOV 24	Search an additional 46,850 records with MEDLINE backfile extension to 1946
NEWS 12	DEC 14	New PNK Field Allows More Precise Crossover among STN Patent Databases
NEWS 13	DEC 18	ReaxysFile available on STN
NEWS 14	DEC 21	CAS Learning Solutions -- a new online training experience
NEWS 15	DEC 22	Value-Added Indexing Improves Access to World Traditional Medicine Patents in CAplus
NEWS 16	JAN 24	The new and enhanced DPCI file on STN has been released
NEWS 17	JAN 26	Improved Timeliness of CAS Indexing Adds Value to USPATFULL and USPAT2 Chemistry Patents
NEWS 18	JAN 26	Updated MeSH vocabulary, new structured abstracts, and other enhancements improve searching in STN reload of MEDLINE
NEWS 19	JAN 28	CABA will be updated weekly

NEWS EXPRESS FEBRUARY 15 10 CURRENT WINDOWS VERSION IS V8.4.2,
AND CURRENT DISCOVER FILE IS DATED 07 JULY 2010.

NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS LOGIN	Welcome Banner and News Items

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN customer agreement. This agreement limits use to scientific research. Use for software development or design, implementation of commercial gateways, or use of CAS and STN data in the building of commercial products is prohibited and may result in loss of user privileges and other penalties.

* * * * * * * * * * * * * * * * STN Columbus * * * * * * * * * * * * * * * *

FILE 'HOME' ENTERED AT 09:46:19 ON 22 FEB 2011

=>
Uploading
THIS COMMAND NOT AVAILABLE IN THE CURRENT FILE
Do you want to switch to the Registry File?
Choice (Y/n):
Switching to the Registry File...
Some commands only work in certain files. For example, the EXPAND command can only be used to look at the index in a file which has an index. Enter "HELP COMMANDS" at an arrow prompt (=>) for a list of commands which can be used in this file.

=> FILE REGISTRY

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	0.23	0.23

FILE 'REGISTRY' ENTERED AT 09:46:58 ON 22 FEB 2011
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 21 FEB 2011 HIGHEST RN 1263357-65-8
DICTIONARY FILE UPDATES: 21 FEB 2011 HIGHEST RN 1263357-65-8

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 26, 2010.

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=>
Uploading C:\Program Files\Stnexp\Queries\10593748.str





chain nodes :
7 8 11 12 13 14 15 16 17 18
ring nodes :
1 2 3 4 5
chain bonds :
3-14 4-7 7-8 8-11 8-12 8-13 14-15 14-16 15-17 15-18
ring bonds :
1-2 1-5 2-3 3-4 4-5
exact/norm bonds :
1-2 1-5 2-3 3-4 3-14 4-5 4-7 7-8 8-11 8-12 8-13 14-15 14-16 15-17
15-18
isolated ring systems :
containing 1 :

G1:O,S,N,CH2

G2:CH2,NH

G3:Cb,Cy,Hy,Ak,Ph

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 7:CLASS 8:CLASS 11:CLASS 12:CLASS
13:CLASS 14:CLASS 15:CLASS 16:CLASS 17:CLASS 18:CLASS

L1 STRUCTURE UPLOADED

```
=> d l1
L1 HAS NO ANSWERS
L1              STR
```



G1 O,S,N,CH2

G2 CH2,NH

G3 Cb,Cy,Hy,Ak,Ph

Structure attributes must be viewed using STN Express query preparation.

```
=> s l1
SAMPLE SEARCH INITIATED 09:47:18 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED -       29 TO ITERATE

100.0% PROCESSED       29 ITERATIONS                              12 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS:  ONLINE  **COMPLETE**
                        BATCH   **COMPLETE**
PROJECTED ITERATIONS:          257 TO      903
PROJECTED ANSWERS:              33 TO      447

L2           12 SEA SSS SAM L1

=> FIL HCAPLUS
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                     0.51       0.74

FILE 'HCAPLUS' ENTERED AT 09:47:24 ON 22 FEB 2011
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2011 AMERICAN CHEMICAL SOCIETY (ACS)
```

FILE COVERS 1907 - 22 Feb 2011 VOL 154 ISS 9
FILE LAST UPDATED: 21 Feb 2011 (20110221/ED)
REVISED CLASS FIELDS (/NCL) LAST RELOADED: Oct 2010
USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Oct 2010

HCAplus now includes complete International Patent Classification (IPC) reclassification data for the fourth quarter of 2010.

CAS Information Use Policies apply and are available at:

http://www.cas.org/legal/infopolicy.html

This file contains CAS Registry Numbers for easy and accurate substance identification.

=> FIL REGISTRY

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	2.99	3.73

FILE 'REGISTRY' ENTERED AT 09:47:34 ON 22 FEB 2011
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

Property values tagged with IC are from the ZIC/VINITI data file provided by InfoChem.

STRUCTURE FILE UPDATES: 21 FEB 2011 HIGHEST RN 1263357-65-8
DICTIONARY FILE UPDATES: 21 FEB 2011 HIGHEST RN 1263357-65-8

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 26, 2010.

Please note that search-term pricing does apply when conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and predicted properties as well as tags indicating availability of experimental property data in the original document. For information on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=> s l1 sss full
FULL SEARCH INITIATED 09:47:40 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 589 TO ITERATE

100.0% PROCESSED 589 ITERATIONS 229 ANSWERS
SEARCH TIME: 00.00.01

```
L3          229 SEA SSS FUL L1

=> FIL HCAPLUS
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                       ENTRY    SESSION
FULL ESTIMATED COST                                   196.86     200.59

FILE 'HCAPLUS' ENTERED AT 09:47:45 ON 22 FEB 2011
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2011 AMERICAN CHEMICAL SOCIETY (ACS)


Copyright of the articles to which records in this database refer is
held by the publishers listed in the PUBLISHER (PB) field (available
for records published or updated in Chemical Abstracts after December
26, 1996), unless otherwise indicated in the original publications.
The CA Lexicon is the copyrighted intellectual property of the
American Chemical Society and is provided to assist you in searching
databases on STN.  Any dissemination, distribution, copying, or storing
of this information, without the prior written consent of CAS, is
strictly prohibited.

FILE COVERS 1907 - 22 Feb 2011  VOL 154 ISS 9
FILE LAST UPDATED: 21 Feb 2011  (20110221/ED)
REVISED CLASS FIELDS (/NCL) LAST RELOADED:  Oct 2010
USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE:  Oct 2010

HCAplus now includes complete International Patent Classification (IPC)
reclassification data for the fourth quarter of 2010.

CAS Information Use Policies apply and are available at:

http://www.cas.org/legal/infopolicy.html

This file contains CAS Registry Numbers for easy and accurate
substance identification.

=> s l3
L4            5 L3

=> s l4 and py<=2004
      25160617 PY<=2004
L5            3 L4 AND PY<=2004

=> d l5 ibib abs hitstr tot
```

L5 ANSWER 1 OF 3 HCAPLUS COPYRIGHT 2011 ACS on STN

ACCESSION NUMBER: 2002:533654 HCAPLUS
DOCUMENT NUMBER: 137:93692
TITLE: Preparation of (quinolinylmethoxyphenylsulfonylmethyl)-substituted pyrrolidinecarboxamides and piperidinecarboxamides as MMP, TNF, and/or aggrecanase inhibitors
INVENTOR(S): Xue, Chu-Biao; Decicco, Carl P.; He, Xiaohua
PATENT ASSIGNEE(S): Bristol-Myers Squibb Company Patent Department, USA
SOURCE: PCT Int. Appl., 133 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002055491	A2	20020718	WO 2002-US760	20020109
WO 2002055491	A3	20030123		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2434044	A1	20020718	CA 2002-2434044	20020109
AU 2002246983	A1	20020724	AU 2002-246983	20020109
US 20030087890	A1	20030508	US 2002-43541	20020109
US 6642255	B2	20031104		
EP 1355648	A2	20031029	EP 2002-714733	20020109
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				

PRIORITY APPLN. INFO.: US 2001-260957P P 20010111
WO 2002-US760 W 20020109

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
OTHER SOURCE(S): MARPAT 137:93692
GI

L5 ANSWER 1 OF 3 HCAPLUS COPYRIGHT 2011 ACS on STN (Continued)



I



II

AB Title compds. I [wherein A = COR5, CO2H, CH2CO2H, CO2R6, CONHOH, CONHOR6, N(OH)CHO, N(OH)COR5, SH, CH2SH, SONHRa, SN2H2Ra, PO3H2, or PO(OH)NHRa; ring B = 3-10 membered (hetero)cycle; Z = absent or (un)substituted (hetero)cyclyl; U = absent or O, NH, N(alkyl),, CO, CO2, OCO, CONH, NHCO, OCO2, etc. X = absent or alkylene, alkenylene, or alkynylene; Y = absent or O, NH, N(alkyl), SO0-2, or CO; Za = (un)substituted (hetero)cyclyl; R1a and R1b = independently H, alkyl, Ph, PhCH2, CH2OR3, or (un)substituted CH2NH2; or CR1aR1b = (hetero)cyclyl; R2 = Q or (un)substituted alkylene-Q, alkenylene-Q, or alkynylene-Q, Q-substituted alkoxy(alkyl), carbamoyl(alkyl), sulfamoyl(alkyl), etc.; R2a = H, alkyl, ORa, (un)substituted CH2NH2, or SO0-2Ra; R2b = H or alkyl; Q = H or (un)substituted (hetero)cyclyl; R3 = Q1 or (un)substituted alkylene-Q1, alkenylene-Q1, or alkynylene-Q1, Q1-substituted alkoxy(alkyl), carbamoyl(alkyl), sulfamoyl(alkyl), etc.; or C(R3)2 = (un)substituted (hetero)cyclyl; Q1 = H or (un)substituted Ph, naphthyl, or heteroaryl; Ra = H, alkyl, Ph, or PhCH2; p = 0-2; R5 = (un)substituted alkyl; R6 = phenyl(alkyl), naphthyl, cycloalkyl, alkylcarbonyloxy, etc.; or pharmaceutically acceptable salt thereof] were prepared as matrix metalloprotease (MMP), tumor necrosis factor (TNF), and aggrecanase inhibitors. For example, the 3-(quinolinylmethoxyphenylsulfonylmethyl)-4-piperidinecarboxamide (3R,4S)-II•2CF3CO2H was prepared in seventeen steps starting from the reaction of N-benzyloxycarbonyl-β-alanine and benzylbromide. Key steps include the cyclization of the 5-aminopentanal intermediate and the addition of 4-mercaptophenol and 4-chloromethyl-2-methylquinoline•HCl. A number of invention compds.

L5 ANSWER 1 OF 3 HCAPLUS COPYRIGHT 2011 ACS on STN (Continued)

exhibited Ki values of ≤ 10 μM against MMP-1, 2, 3, 9, and 13. Thus, I are useful for the treatment of inflammatory disorders and thromboembolic disorder (no data).

IT 441297-34-3P
RL: PAC (Pharmacological activity); RCT (Reactant); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); RACT (Reactant or reagent); USES (Uses)
(MMP, TNF, and/or aggrecanase inhibitor; preparation of (quinolinylmethoxyphenylsulfonylmethyl)-substituted pyrrolidinecarboxamides and piperidinecarboxamides as MMP, TNF, and/or aggrecanase inhibitors)

RN 441297-34-3 HCAPLUS
CN 1-Pyrrolidinecarboxylic acid, 3-[(hydroxyamino)carbonyl]-4-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]sulfonyl]methyl]-, (3R,4S)-, 1,1-dimethylethyl ester, 2,2,2-trifluoroacetate (1:1) (CA INDEX NAME)

CM 1

CRN 441297-33-2
CMF C28 H33 N3 O7 S

Absolute stereochemistry.

PAGE 1-A



L5 ANSWER 1 OF 3 HCAPLUS COPYRIGHT 2011 ACS on STN (Continued)

PAGE 2-A



CM 2

CRN 76-05-1
CMF C2 H F3 O2

IT 441297-33-2P 441297-35-4P 441297-36-5P
441297-37-6P 441297-38-7P 441297-39-8P
441297-40-1P
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(MMP, TNF, and/or aggrecanase inhibitor; preparation of (quinolinylmethoxyphenylsulfonylmethyl)-substituted pyrrolidinecarboxamides and piperidinecarboxamides as MMP, TNF, and/or aggrecanase inhibitors)

RN 441297-33-2 HCAPLUS
CN 1-Pyrrolidinecarboxylic acid, 3-[(hydroxyamino)carbonyl]-4-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]sulfonyl]methyl]-, 1,1-dimethylethyl ester, (3R,4S)- (CA INDEX NAME)

Absolute stereochemistry.

L5 ANSWER 1 OF 3 HCAPLUS COPYRIGHT 2011 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A



RN 441297-35-4 HCAPLUS
CN 3-Pyrrolidinecarboxamide, N-hydroxy-4-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]sulfonyl]methyl]-, (3R,4S)- (CA INDEX NAME)

Absolute stereochemistry.

L5 ANSWER 1 OF 3 HCAPLUS COPYRIGHT 2011 ACS on STN (Continued)



RN 441297-36-5 HCAPLUS
CN 3-Pyrrolidinecarboxamide, N-hydroxy-4-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]sulfonyl]methyl]-, (3R,4S)-, 2,2,2-trifluoroacetate (1:2) (CA INDEX NAME)

CM 1

CRN 441297-35-4
CMF C23 H25 N3 O5 S

Absolute stereochemistry.

L5 ANSWER 1 OF 3 HCAPLUS COPYRIGHT 2011 ACS on STN (Continued)



CM 2

CRN 76-05-1
CMF C2 H F3 O2

RN 441297-37-6 HCAPLUS
CN 3-Pyrrolidinecarboxamide, N-hydroxy-1-(1-methylethyl)-4-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]sulfonyl]methyl]-, (3R,4S)- (CA INDEX NAME)

Absolute stereochemistry.

L5 ANSWER 1 OF 3 HCAPLUS COPYRIGHT 2011 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A

RN 441297-38-7 HCAPLUS
CN 3-Pyrrolidinecarboxamide, N-hydroxy-1-(1-methylethyl)-4-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]sulfonyl]methyl]-, (3R,4S)-, 2,2,2-trifluoroacetate (1:2) (CA INDEX NAME)

CM 1

CRN 441297-37-6
CMF C26 H31 N3 O5 S

Absolute stereochemistry.

L5 ANSWER 1 OF 3 HCAPLUS COPYRIGHT 2011 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A

CM 2

CRN 76-05-1
CMF C2 H F3 O2

L5 ANSWER 1 OF 3 HCAPLUS COPYRIGHT 2011 ACS on STN (Continued)
RN 441297-39-8 HCAPLUS
CN 3-Pyrrolidinecarboxamide, N-hydroxy-4-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]sulfonyl]methyl]-1-(2-propyn-1-yl)-, (3R,4S)-(CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A



CM 2

CRN 76-05-1
CMF C2 H F3 O2

L5 ANSWER 1 OF 3 HCAPLUS COPYRIGHT 2011 ACS on STN (Continued)

RN 441297-40-1 HCAPLUS
CN 3-Pyrrolidinecarboxamide, N-hydroxy-4-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]sulfonyl]methyl]-1-(2-propyn-1-yl)-, (3R,4S)-, 2,2,2-trifluoroacetate (1:2) (CA INDEX NAME)

CM 1

L5 ANSWER 1 OF 3 HCAPLUS COPYRIGHT 2011 ACS on STN (Continued)

IT 1101037-97-1 1101037-98-2 1101037-99-3
1101038-00-9 1101038-01-0 1101038-02-1
1101038-03-2 1101038-04-3 1101038-05-4
1101038-06-5 1101038-07-6 1101038-08-7
1101038-09-8 1101038-10-1 1101038-11-2
1101038-12-3 1101038-13-4 1101038-14-5
1101038-15-6 1101038-16-7 1101038-17-8
1101038-18-9 1101038-19-0 1101038-20-3
1101038-21-4 1101038-22-5 1101038-23-6
1101038-24-7 1101038-25-8 1101038-26-9
1101038-27-0 1101038-28-1 1101038-29-2
1101038-30-5 1101038-31-6 1101038-32-7
1101038-33-8 1101038-34-9 1101038-35-0
1101038-36-1 1101038-37-2 1101038-38-3
1101038-39-4 1101038-40-7 1101038-41-8
1101038-42-9 1101038-43-0 1101038-44-1
1101038-45-2 1101038-46-3 1101038-47-4
1101038-48-5 1101038-49-6 1101038-90-7
1101038-91-8 1101038-92-9 1101038-93-0
1101038-94-1 1101038-95-2 1101038-96-3
1101038-97-4 1101038-98-5 1101038-99-6
1101039-00-2 1101039-01-3 1101039-02-4
1101039-03-5 1101039-04-6 1101039-05-7
1101039-06-8 1101039-07-9 1101039-08-0
1101039-09-1 1101039-10-4 1101039-11-5
1101039-12-6 1101039-13-7 1101039-14-8
1101039-15-9 1101039-16-0 1101039-17-1
1101039-18-2 1101039-19-3 1101039-20-6
1101039-21-7 1101039-22-8 1101041-14-8
1101041-15-9 1101041-16-0 1101041-17-1
1101041-18-2 1101041-19-3 1101041-20-6
1101041-21-7 1101041-22-8 1101041-23-9
1101041-24-0 1101041-25-1 1101041-26-2
1101041-27-3 1101041-28-4 1101041-29-5
1101041-30-8 1101041-31-9 1101041-32-0
1101041-33-1 1101041-34-2 1101041-35-3
1101041-36-4 1101041-37-5 1101041-38-6
1101041-39-7 1101041-40-0 1101041-41-1
1101041-84-2 1101041-85-3 1101041-86-4
1101041-87-5 1101041-88-6 1101041-89-7
1101041-90-0 1101041-91-1 1101041-92-2
1101041-93-3 1101041-94-4 1101041-95-5
1101041-96-6 1101041-97-7 1101041-98-8
1101041-99-9 1101042-00-5 1101042-01-6
1101042-02-7 1101042-03-8 1101042-04-9
1101042-05-0 1101042-06-1 1101042-07-2
1101042-08-3 1101042-09-4 1101042-10-7
1101042-11-8 1101042-12-9 1101042-13-0
1101042-14-1 1101042-15-2 1101042-16-3
1101042-17-4 1101042-18-5 1101042-19-6
1101042-20-9 1101042-21-0 1101042-22-1
1101042-23-2 1101042-24-3 1101042-25-4
1101042-26-5 1101042-27-6 1101042-28-7
1101042-29-8 1101042-30-1 1101042-31-2
1101042-32-3 1101042-33-4 1101042-34-5
1101042-35-6 1101042-36-7 1101042-37-8
1101042-38-9 1101042-39-0 1101042-49-3

L5 ANSWER 1 OF 3 HCAPLUS COPYRIGHT 2011 ACS on STN (Continued)

1101043-60-0 1101043-61-1 1101043-62-2
1101043-63-3 1101043-64-4 1101043-65-5
1101043-66-6 1101043-67-7 1101043-68-8
1101043-69-9 1101043-70-2 1101043-71-3
1101043-72-4 1101043-73-5 1101043-74-6
1101043-75-7 1101043-76-8 1101043-77-9
1101043-78-0 1101043-79-1 1101043-80-4
1101043-81-5 1101043-82-6 1101043-83-7
1101043-84-8 1101044-58-9 1101044-59-0
1101044-60-3 1101044-61-4 1101044-62-5
1101044-63-6 1101044-64-7 1101044-65-8

RL: PRPH (Prophetic)
(Preparation of (quinolinylmethoxyphenylsulfonylmethyl)-substituted pyrrolidinecarboxamides and piperidinecarboxamides as MMP, TNF, and/or aggrecanase inhibitors)

RN 1101037-97-1 HCAPLUS
CN 3-Pyrrolidinecarboxamide, N-hydroxy-1-methyl-4-[[[4-(3-pyridinylmethoxy)phenyl]sulfonyl]methyl]-, (3R,4S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 1101037-98-2 HCAPLUS
CN 3-Pyrrolidinecarboxamide, N-hydroxy-1-methyl-4-[[[4-(4-pyridinylmethoxy)phenyl]sulfonyl]methyl]-, (3R,4S)- (CA INDEX NAME)

Absolute stereochemistry.

L5 ANSWER 1 OF 3 HCAPLUS COPYRIGHT 2011 ACS on STN (Continued)



RN 1101037-99-3 HCAPLUS
CN 3-Pyrrolidinecarboxamide, 4-[[[4-[(2,6-dimethyl-4-pyridinyl)methoxy]phenyl]sulfonyl]methyl]-N-hydroxy-1-methyl-, (3R,4S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 1101038-00-9 HCAPLUS
CN 3-Pyrrolidinecarboxamide, 4-[[[4-[(2-chloro-6-methyl-4-pyridinyl)methoxy]phenyl]sulfonyl]methyl]-N-hydroxy-1-methyl-, (3R,4S)- (CA INDEX NAME)

Absolute stereochemistry.

L5 ANSWER 1 OF 3 HCAPLUS COPYRIGHT 2011 ACS on STN (Continued)



RN 1101038-01-0 HCAPLUS
CN 3-Pyrrolidinecarboxamide, 4-[[[4-[(2-chloro-6-methoxy-4-pyridinyl)methoxy]phenyl]sulfonyl]methyl]-N-hydroxy-1-methyl-, (3R,4S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 1101038-02-1 HCAPLUS
CN 3-Pyrrolidinecarboxamide, N-hydroxy-1-methyl-4-[[[4-(4-quinolinylmethoxy)phenyl]sulfonyl]methyl]-, (3R,4S)- (CA INDEX NAME)

Absolute stereochemistry.

L5 ANSWER 1 OF 3 HCAPLUS COPYRIGHT 2011 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A

RN 1101038-03-2 HCAPLUS
CN 3-Pyrrolidinecarboxamide, N-hydroxy-1-methyl-4-[[[4-(5-quinolinylmethoxy)phenyl]sulfonyl]methyl]-, (3R,4S)- (CA INDEX NAME)

Absolute stereochemistry.

L5 ANSWER 1 OF 3 HCAPLUS COPYRIGHT 2011 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A

RN 1101038-04-3 HCAPLUS
CN 3-Pyrrolidinecarboxamide, N-hydroxy-1-methyl-4-[[[4-(6-quinolinylmethoxy)phenyl]sulfonyl]methyl]-, (3R,4S)- (CA INDEX NAME)

Absolute stereochemistry.

L5 ANSWER 1 OF 3 HCAPLUS COPYRIGHT 2011 ACS on STN (Continued)



RN 1101038-05-4 HCAPLUS
CN 3-Pyrrolidinecarboxamide, N-hydroxy-4-[[[4-(5-isoquinolinylmethoxy)phenyl]sulfonyl]methyl]-1-methyl-, (3R,4S)- (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



L5 ANSWER 1 OF 3 HCAPLUS COPYRIGHT 2011 ACS on STN (Continued)

PAGE 2-A



RN 1101038-06-5 HCAPLUS
CN 3-Pyrrolidinecarboxamide, N-hydroxy-1-methyl-4-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]sulfonyl]methyl]-, (3R,4S)- (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A



RN 1101038-07-6 HCAPLUS
CN 3-Pyrrolidinecarboxamide, N-hydroxy-4-[[[4-[(2-methoxy-4-quinolinyl)methoxy]phenyl]sulfonyl]methyl]-1-methyl-, (3R,4S)- (CA INDEX

L5 ANSWER 1 OF 3 HCAPLUS COPYRIGHT 2011 ACS on STN (Continued)
NAME)

Absolute stereochemistry.

PAGE 1-A



PAGE 2-A

RN 1101038-08-7 HCAPLUS
CN 3-Pyrrolidinecarboxamide, 4-[[[4-[(2-amino-4-quinolinyl)methoxy]phenyl]sulfonyl]methyl]-N-hydroxy-1-methyl-, (3R,4S)- (CA INDEX NAME)

Absolute stereochemistry.

L5 ANSWER 1 OF 3 HCAPLUS COPYRIGHT 2011 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A

RN 1101038-09-8 HCAPLUS
CN 3-Pyrrolidinecarboxamide, N-hydroxy-1-methyl-4-[[[4-[2-(4-quinolinyl)ethoxy]phenyl]sulfonyl]methyl]-, (3R,4S)- (CA INDEX NAME)

Absolute stereochemistry.

L5 ANSWER 1 OF 3 HCAPLUS COPYRIGHT 2011 ACS on STN (Continued)



RN 1101038-10-1 HCAPLUS
CN 3-Pyrrolidinecarboxamide, N-hydroxy-1-methyl-4-[[[4-[2-(5-quinolinyl)ethoxy]phenyl]sulfonyl]methyl]-, (3R,4S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 1101038-11-2 HCAPLUS
CN 3-Pyrrolidinecarboxamide, N-hydroxy-1-methyl-4-[[[4-[2-(6-quinolinyl)ethoxy]phenyl]sulfonyl]methyl]-, (3R,4S)- (CA INDEX NAME)

Absolute stereochemistry.

L5 ANSWER 1 OF 3 HCAPLUS COPYRIGHT 2011 ACS on STN (Continued)



RN 1101038-12-3 HCAPLUS
CN 3-Pyrrolidinecarboxamide, N-hydroxy-4-[[[4-[2-(5-isoquinolinyl)ethoxy]phenyl]sulfonyl]methyl]-1-methyl-, (3R,4S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 1101038-13-4 HCAPLUS
CN 3-Pyrrolidinecarboxamide, N-hydroxy-1-methyl-4-[[[4-[2-(2-methyl-4-quinolinyl)ethoxy]phenyl]sulfonyl]methyl]-, (3R,4S)- (CA INDEX NAME)

Absolute stereochemistry.

L5 ANSWER 1 OF 3 HCAPLUS COPYRIGHT 2011 ACS on STN (Continued)



RN 1101038-14-5 HCAPLUS
CN 3-Pyrrolidinecarboxamide, N-hydroxy-4-[[[4-[2-(2-methoxy-4-quinolinyl)ethoxy]phenyl]sulfonyl]methyl]-1-methyl-, (3R,4S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 1101038-15-6 HCAPLUS
CN 3-Pyrrolidinecarboxamide, 4-[[[4-[2-(2-amino-4-quinolinyl)ethoxy]phenyl]sulfonyl]methyl]-N-hydroxy-1-methyl-, (3R,4S)- (CA INDEX NAME)

Absolute stereochemistry.

L5 ANSWER 1 OF 3 HCAPLUS COPYRIGHT 2011 ACS on STN (Continued)



RN 1101038-16-7 HCAPLUS
CN 3-Pyrrolidinecarboxamide, N-hydroxy-1-methyl-4-[[[4-(phenoxymethyl)phenyl]sulfonyl]methyl]-, (3R,4S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 1101038-17-8 HCAPLUS
CN 3-Pyrrolidinecarboxamide, 4-[[[4-[(3,5-dimethylphenoxy)methyl]phenyl]sulfonyl]methyl]-N-hydroxy-1-methyl-, (3R,4S)- (CA INDEX NAME)

Absolute stereochemistry.

L5 ANSWER 1 OF 3 HCAPLUS COPYRIGHT 2011 ACS on STN (Continued)



RN 1101038-18-9 HCAPLUS
CN 3-Pyrrolidinecarboxamide, 4-[[[4-[(3,5-dichlorophenoxy)methyl]phenyl]sulfonyl]methyl]-N-hydroxy-1-methyl-, (3R,4S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 1101038-19-0 HCAPLUS
CN 3-Pyrrolidinecarboxamide, 4-[[[4-[[3,5-bis(trifluoromethyl)phenoxy]methyl]phenyl]sulfonyl]methyl]-N-hydroxy-1-methyl-, (3R,4S)- (CA INDEX NAME)

Absolute stereochemistry.

L5 ANSWER 1 OF 3 HCAPLUS COPYRIGHT 2011 ACS on STN (Continued)



RN 1101038-20-3 HCAPLUS
CN 3-Pyrrolidinecarboxamide, 4-[[[4-[[(2,6-dimethyl-4-pyridinyl)oxy]methyl]phenyl]sulfonyl]methyl]-N-hydroxy-1-methyl-, (3R,4S)-
(CA INDEX NAME)

Absolute stereochemistry.



RN 1101038-21-4 HCAPLUS
CN 3-Pyrrolidinecarboxamide, N-hydroxy-1-methyl-4-[[[4-[(4-pyridinyloxy)methyl]phenyl]sulfonyl]methyl]-, (3R,4S)- (CA INDEX NAME)

Absolute stereochemistry.

L5 ANSWER 1 OF 3 HCAPLUS COPYRIGHT 2011 ACS on STN (Continued)



RN 1101038-22-5 HCAPLUS
CN 3-Pyrrolidinecarboxamide, 4-[[[4-[[(2-chloro-6-methyl-4-pyridinyl)oxy]methyl]phenyl]sulfonyl]methyl]-N-hydroxy-1-methyl-, (3R,4S)-
(CA INDEX NAME)

Absolute stereochemistry.



RN 1101038-23-6 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.

L5 ANSWER 1 OF 3 HCAPLUS COPYRIGHT 2011 ACS on STN (Continued)



RN 1101038-24-7 HCAPLUS
CN 3-Pyrrolidinecarboxamide, N-hydroxy-1-methyl-4-[[[4-[(4-quinolinyloxy)methyl]phenyl]sulfonyl]methyl]-, (3R,4S)- (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



L5 ANSWER 1 OF 3 HCAPLUS COPYRIGHT 2011 ACS on STN (Continued)

PAGE 2-A

RN 1101038-26-9 HCAPLUS
CN 3-Pyrrolidinecarboxamide, N-hydroxy-1-methyl-4-[[[4-[(6-quinolinyloxy)methyl]phenyl]sulfonyl]methyl]-, (3R,4S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 1101038-27-0 HCAPLUS
CN 3-Pyrrolidinecarboxamide, N-hydroxy-4-[[[4-[(5-isoquinolinyloxy)methyl]phenyl]sulfonyl]methyl]-1-methyl-, (3R,4S)- (CA INDEX NAME)

Absolute stereochemistry.

L5 ANSWER 1 OF 3 HCAPLUS COPYRIGHT 2011 ACS on STN (Continued)

PAGE 2-A



RN 1101038-25-8 HCAPLUS
CN 3-Pyrrolidinecarboxamide, N-hydroxy-1-methyl-4-[[[4-[(5-quinolinyloxy)methyl]phenyl]sulfonyl]methyl]-, (3R,4S)- (CA INDEX NAME)

Absolute stereochemistry.

PAGE 1-A



L5 ANSWER 1 OF 3 HCAPLUS COPYRIGHT 2011 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A



RN 1101038-28-1 HCAPLUS
CN 3-Pyrrolidinecarboxamide, N-hydroxy-1-methyl-4-[[[4-[[(2-methyl-4-quinolinyl)oxy]methyl]phenyl]sulfonyl]methyl]-, (3R,4S)- (CA INDEX NAME)

Absolute stereochemistry.

L5 ANSWER 1 OF 3 HCAPLUS COPYRIGHT 2011 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A

RN 1101038-29-2 HCAPLUS
CN 3-Pyrrolidinecarboxamide, N-hydroxy-4-[[[4-(1H-indol-5-yloxy)phenyl]sulfonyl]methyl]-1-methyl-, (3R,4S)- (CA INDEX NAME)

Absolute stereochemistry.

L5 ANSWER 1 OF 3 HCAPLUS COPYRIGHT 2011 ACS on STN (Continued)



RN 1101038-30-5 HCAPLUS
CN 3-Pyrrolidinecarboxamide, N-hydroxy-1-methyl-4-[[[4-[(1-methyl-1H-indol-5-yl)oxy]phenyl]sulfonyl]methyl]-, (3R,4S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 1101038-31-6 HCAPLUS
CN 3-Pyrrolidinecarboxamide, 4-[[[4-[(1-ethyl-1H-indol-5-yl)oxy]phenyl]sulfonyl]methyl]-N-hydroxy-1-methyl-, (3R,4S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 1101038-32-7 HCAPLUS
CN 3-Pyrrolidinecarboxamide, N-hydroxy-4-[[[4-[(1H-indol-5-yloxy)methyl]phenyl]sulfonyl]methyl]-1-methyl-, (3R,4S)- (CA INDEX NAME)

L5 ANSWER 1 OF 3 HCAPLUS COPYRIGHT 2011 ACS on STN (Continued)

Absolute stereochemistry.



RN 1101038-33-8 HCAPLUS
CN 3-Pyrrolidinecarboxamide, N-hydroxy-1-methyl-4-[[[4-[[(1-methyl-1H-indol-5-yl)oxy]methyl]phenyl]sulfonyl]methyl]-, (3R,4S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 1101038-34-9 HCAPLUS
CN 3-Pyrrolidinecarboxamide, 4-[[[4-[[(1-ethyl-1H-indol-5-yl)oxy]methyl]phenyl]sulfonyl]methyl]-N-hydroxy-1-methyl-, (3R,4S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 1101038-35-0 HCAPLUS
CN 3-Pyrrolidinecarboxamide, N-hydroxy-4-[[[4-(1H-indol-5-

L5 ANSWER 1 OF 3 HCAPLUS COPYRIGHT 2011 ACS on STN (Continued)
ylmethoxy)phenyl]sulfonyl]methyl]-1-methyl-, (3R,4S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 1101038-36-1 HCAPLUS
CN 3-Pyrrolidinecarboxamide, N-hydroxy-1-methyl-4-[[[4-[(1-methyl-1H-indol-5-yl)methoxy]phenyl]sulfonyl]methyl]-, (3R,4S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 1101038-37-2 HCAPLUS
CN 3-Pyrrolidinecarboxamide, 4-[[[4-(1H-benzimidazol-1-ylmethyl)phenyl]sulfonyl]methyl]-N-hydroxy-1-methyl-, (3R,4S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 1101038-38-3 HCAPLUS
CN 3-Pyrrolidinecarboxamide, 4-[[[4-[(1-ethyl-1H-indol-5-

L5 ANSWER 1 OF 3 HCAPLUS COPYRIGHT 2011 ACS on STN (Continued)
yl)methoxy]phenyl]sulfonyl]methyl]-N-hydroxy-1-methyl-, (3R,4S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 1101038-39-4 HCAPLUS
CN 3-Pyrrolidinecarboxamide, 4-[[[4-[2-(1H-benzimidazol-1-yl)ethyl]phenyl]sulfonyl]methyl]-N-hydroxy-1-methyl-, (3R,4S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 1101038-40-7 HCAPLUS
CN 3-Pyrrolidinecarboxamide, 4-[[[4-(1H-benzotriazol-1-ylmethyl)phenyl]sulfonyl]methyl]-N-hydroxy-1-methyl-, (3R,4S)- (CA INDEX NAME)

Absolute stereochemistry.

L5 ANSWER 1 OF 3 HCAPLUS COPYRIGHT 2011 ACS on STN (Continued)



RN 1101038-41-8 HCAPLUS
CN 3-Pyrrolidinecarboxamide, 4-[[[4-[2-(1H-benzotriazol-1-yl)ethyl]phenyl]sulfonyl]methyl]-N-hydroxy-1-methyl-, (3R,4S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 1101038-42-9 HCAPLUS
CN 3-Pyrrolidinecarboxamide, 4-[[[4-[(2,4-dimethyl-5-thiazolyl)methoxy]phenyl]sulfonyl]methyl]-N-hydroxy-1-methyl-, (3R,4S)- (CA INDEX NAME)

Absolute stereochemistry.



L5 ANSWER 1 OF 3 HCAPLUS COPYRIGHT 2011 ACS on STN (Continued)
RN 1101038-43-0 HCAPLUS
CN 3-Pyrrolidinecarboxamide, 4-[[[4-[(2,5-dimethyl-4-thiazolyl)methoxy]phenyl]sulfonyl]methyl]-N-hydroxy-1-methyl-, (3R,4S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 1101038-44-1 HCAPLUS
CN 3-Pyrrolidinecarboxamide, 4-[[[4-[(4,5-dimethyl-2-thiazolyl)methoxy]phenyl]sulfonyl]methyl]-N-hydroxy-1-methyl-, (3R,4S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 1101038-45-2 HCAPLUS
CN 3-Pyrrolidinecarboxamide, N-hydroxy-1-methyl-4-[[[4-[[2-(1-methylethyl)-4-thiazolyl]methoxy]phenyl]sulfonyl]methyl]-, (3R,4S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 1101038-46-3 HCAPLUS

L5 ANSWER 1 OF 3 HCAPLUS COPYRIGHT 2011 ACS on STN (Continued)
CN 3-Pyrrolidinecarboxamide, N-hydroxy-1-methyl-4-[[[4-[(5-methyl-4-isoxazolyl)methoxy]phenyl]sulfonyl]methyl]-, (3R,4S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 1101038-47-4 HCAPLUS
CN 3-Pyrrolidinecarboxamide, N-hydroxy-1-methyl-4-[[[4-[[2-(1-methylethyl)-5-thiazolyl]methoxy]phenyl]sulfonyl]methyl]-, (3R,4S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 1101038-48-5 HCAPLUS
CN 3-Pyrrolidinecarboxamide, 4-[[[4-(2-butyn-1-yloxy)phenyl]sulfonyl]methyl]-N-hydroxy-1-methyl-, (3R,4S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 1101038-49-6 HCAPLUS
CN 3-Pyrrolidinecarboxamide, N-hydroxy-1-methyl-4-[[[4-(2-pentyn-1-yloxy)phenyl]sulfonyl]methyl]-, (3R,4S)- (CA INDEX NAME)

L5 ANSWER 1 OF 3 HCAPLUS COPYRIGHT 2011 ACS on STN (Continued)

Absolute stereochemistry.



RN 1101038-90-7 HCAPLUS
CN 3-Pyrrolidinecarboxamide, N-hydroxy-1-methyl-4-[(phenylsulfonyl)methyl]-, (3R,4S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 1101038-91-8 HCAPLUS
CN 3-Pyrrolidinecarboxamide, N-hydroxy-1-methyl-4-[[(4-methylphenyl)sulfonyl]methyl]-, (3R,4S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 1101038-92-9 HCAPLUS
CN 3-Pyrrolidinecarboxamide, N-hydroxy-4-[[(4-methoxyphenyl)sulfonyl]methyl]-1-methyl-, (3R,4S)- (CA INDEX NAME)

L5 ANSWER 1 OF 3 HCAPLUS COPYRIGHT 2011 ACS on STN (Continued)

Absolute stereochemistry.



RN 1101038-93-0 HCAPLUS
CN 3-Pyrrolidinecarboxamide, 4-[[(4-ethoxyphenyl)sulfonyl]methyl]-N-hydroxy-1-methyl-, (3R,4S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 1101038-94-1 HCAPLUS
CN 3-Pyrrolidinecarboxamide, N-hydroxy-1-methyl-4-[[(4-propoxyphenyl)sulfonyl]methyl]-, (3R,4S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 1101038-95-2 HCAPLUS
CN 3-Pyrrolidinecarboxamide, N-hydroxy-1-methyl-4-[[[4-(1-

L5 ANSWER 1 OF 3 HCAPLUS COPYRIGHT 2011 ACS on STN (Continued)
methylethoxy)phenyl]sulfonyl]methyl]-, (3R,4S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 1101038-96-3 HCAPLUS
CN 3-Pyrrolidinecarboxamide, N-hydroxy-1-methyl-4-[[[4-(2-methylpropoxy)phenyl]sulfonyl]methyl]-, (3R,4S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 1101038-97-4 HCAPLUS
CN 3-Pyrrolidinecarboxamide, 4-[[[4-(1,1-dimethylethoxy)phenyl]sulfonyl]methyl]-N-hydroxy-1-methyl-, (3R,4S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 1101038-98-5 HCAPLUS
CN 3-Pyrrolidinecarboxamide, 4-[[[4-(cyclopropyloxy)phenyl]sulfonyl]methyl]-N-hydroxy-1-methyl-, (3R,4S)- (CA INDEX NAME)

L5 ANSWER 1 OF 3 HCAPLUS COPYRIGHT 2011 ACS on STN (Continued)
Absolute stereochemistry.



RN 1101038-99-6 HCAPLUS
CN 3-Pyrrolidinecarboxamide, 4-[[[4-(cyclobutyloxy)phenyl]sulfonyl]methyl]-N-hydroxy-1-methyl-, (3R,4S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 1101039-00-2 HCAPLUS
CN 3-Pyrrolidinecarboxamide, 4-[[[4-(cyclopentyloxy)phenyl]sulfonyl]methyl]-N-hydroxy-1-methyl-, (3R,4S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 1101039-01-3 HCAPLUS
CN 3-Pyrrolidinecarboxamide, 4-[[[4-(cyclohexyloxy)phenyl]sulfonyl]methyl]-N-hydroxy-1-methyl-, (3R,4S)- (CA INDEX NAME)

Absolute stereochemistry.

L5 ANSWER 1 OF 3 HCAPLUS COPYRIGHT 2011 ACS on STN (Continued)



RN 1101039-02-4 HCAPLUS
CN 3-Pyrrolidinecarboxamide, N-hydroxy-1-methyl-4-[[(4-phenoxyphenyl)sulfonyl]methyl]-, (3R,4S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 1101039-03-5 HCAPLUS
CN 3-Pyrrolidinecarboxamide, 4-[[[4-(3,5-dimethylphenoxy)phenyl]sulfonyl]methyl]-N-hydroxy-1-methyl-, (3R,4S)-(CA
INDEX NAME)

Absolute stereochemistry.



RN 1101039-04-6 HCAPLUS
CN 3-Pyrrolidinecarboxamide, 4-[[[4-(3,5-dichlorophenoxy)phenyl]sulfonyl]methyl]-N-hydroxy-1-methyl-, (3R,4S)-(CA

L5 ANSWER 1 OF 3 HCAPLUS COPYRIGHT 2011 ACS on STN (Continued)
CN 3-Pyrrolidinecarboxamide, N-hydroxy-1-methyl-4-[[[4-(4-methylphenoxy)phenyl]sulfonyl]methyl]-, (3R,4S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 1101039-08-0 HCAPLUS
CN 3-Pyrrolidinecarboxamide, 4-[[[4-(4-chlorophenoxy)phenyl]sulfonyl]methyl]-N-hydroxy-1-methyl-, (3R,4S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 1101039-09-1 HCAPLUS
CN 3-Pyrrolidinecarboxamide, N-hydroxy-1-methyl-4-[[[4-(4-pyridinyloxy)phenyl]sulfonyl]methyl]-, (3R,4S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 1101039-10-4 HCAPLUS
CN 3-Pyrrolidinecarboxamide, 4-[[[4-[(2,6-dimethyl-4-pyridinyl)oxy]phenyl]sulfonyl]methyl]-N-hydroxy-1-methyl-, (3R,4S)- (CA INDEX NAME)

L5 ANSWER 1 OF 3 HCAPLUS COPYRIGHT 2011 ACS on STN (Continued)
INDEX NAME)

Absolute stereochemistry.



RN 1101039-05-7 HCAPLUS
CN 3-Pyrrolidinecarboxamide, N-hydroxy-1-methyl-4-[[[4-(3-methylphenoxy)phenyl]sulfonyl]methyl]-, (3R,4S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 1101039-06-8 HCAPLUS
CN 3-Pyrrolidinecarboxamide, 4-[[[4-(3-chlorophenoxy)phenyl]sulfonyl]methyl]-N-hydroxy-1-methyl-, (3R,4S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 1101039-07-9 HCAPLUS

L5 ANSWER 1 OF 3 HCAPLUS COPYRIGHT 2011 ACS on STN (Continued)

Absolute stereochemistry.



RN 1101039-11-5 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.



RN 1101039-12-6 HCAPLUS
CN 3-Pyrrolidinecarboxamide, N-hydroxy-1-methyl-4-[[[4-(5-quinolinyloxy)phenyl]sulfonyl]methyl]-, (3R,4S)- (CA INDEX NAME)

Absolute stereochemistry.



L5 ANSWER 1 OF 3 HCAPLUS COPYRIGHT 2011 ACS on STN (Continued)

RN 1101039-13-7 HCAPLUS
CN 3-Pyrrolidinecarboxamide, N-hydroxy-1-methyl-4-[[[4-(6-quinolinyloxy)phenyl]sulfonyl]methyl]-, (3R,4S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 1101039-14-8 HCAPLUS
CN 3-Pyrrolidinecarboxamide, N-hydroxy-4-[[[4-(5-isoquinolinyloxy)phenyl]sulfonyl]methyl]-1-methyl-, (3R,4S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 1101039-15-9 HCAPLUS
CN 3-Pyrrolidinecarboxamide, N-hydroxy-1-methyl-4-[[[4-[(2-methyl-4-quinolinyl)oxy]phenyl]sulfonyl]methyl]-, (3R,4S)- (CA INDEX NAME)

Absolute stereochemistry.

L5 ANSWER 1 OF 3 HCAPLUS COPYRIGHT 2011 ACS on STN (Continued)



RN 1101039-16-0 HCAPLUS
CN 3-Pyrrolidinecarboxamide, N-hydroxy-1-methyl-4-[[[4-(phenylmethoxy)phenyl]sulfonyl]methyl]-, (3R,4S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 1101039-17-1 HCAPLUS
CN 3-Pyrrolidinecarboxamide, 4-[[[4-[(3,5-dimethylphenyl)methoxy]phenyl]sulfonyl]methyl]-N-hydroxy-1-methyl-, (3R,4S)- (CA INDEX NAME)

Absolute stereochemistry.

L5 ANSWER 1 OF 3 HCAPLUS COPYRIGHT 2011 ACS on STN (Continued)



RN 1101039-18-2 HCAPLUS
CN 3-Pyrrolidinecarboxamide, 4-[[[4-[(3,5-dichlorophenyl)methoxy]phenyl]sulfonyl]methyl]-N-hydroxy-1-methyl-, (3R,4S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 1101039-19-3 HCAPLUS
CN 3-Pyrrolidinecarboxamide, 4-[[[4-[(3,5-dimethoxyphenyl)methoxy]phenyl]sulfonyl]methyl]-N-hydroxy-1-methyl-, (3R,4S)- (CA INDEX NAME)

Absolute stereochemistry.

L5 ANSWER 1 OF 3 HCAPLUS COPYRIGHT 2011 ACS on STN (Continued)



RN 1101039-20-6 HCAPLUS
CN 3-Pyrrolidinecarboxamide, 4-[[[4-[(3,5-dibromophenyl)methoxy]phenyl]sulfonyl]methyl]-N-hydroxy-1-methyl-, (3R,4S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 1101039-21-7 HCAPLUS
CN 3-Pyrrolidinecarboxamide, 4-[[[4-[[3,5-bis(trifluoromethyl)phenyl]methoxy]phenyl]sulfonyl]methyl]-N-hydroxy-1-methyl-, (3R,4S)- (CA INDEX NAME)

Absolute stereochemistry.

L5 ANSWER 1 OF 3 HCAPLUS COPYRIGHT 2011 ACS on STN (Continued)



RN 1101039-22-8 HCAPLUS
CN 3-Pyrrolidinecarboxamide, N-hydroxy-1-methyl-4-[[[4-(2-pyridinylmethoxy)phenyl]sulfonyl]methyl]-, (3R,4S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 1101041-14-8 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.

L5 ANSWER 1 OF 3 HCAPLUS COPYRIGHT 2011 ACS on STN (Continued)



RN 1101041-15-9 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.



RN 1101041-16-0 HCAPLUS
CN 3-Furancarboxamide, tetrahydro-N-hydroxy-4-[[[4-[(4-quinolinyloxy)methyl]phenyl]sulfonyl]methyl]-, (3R,4S)- (CA INDEX NAME)

Absolute stereochemistry.

L5 ANSWER 1 OF 3 HCAPLUS COPYRIGHT 2011 ACS on STN (Continued)



RN 1101041-17-1 HCAPLUS
CN 3-Furancarboxamide, tetrahydro-N-hydroxy-4-[[[4-[(5-quinolinyloxy)methyl]phenyl]sulfonyl]methyl]-, (3R,4S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 1101041-18-2 HCAPLUS
CN 3-Furancarboxamide, tetrahydro-N-hydroxy-4-[[[4-[(6-quinolinyloxy)methyl]phenyl]sulfonyl]methyl]-, (3R,4S)- (CA INDEX NAME)

L5 ANSWER 1 OF 3 HCAPLUS COPYRIGHT 2011 ACS on STN (Continued)

Absolute stereochemistry.



RN 1101041-19-3 HCAPLUS
CN 3-Furancarboxamide, tetrahydro-N-hydroxy-4-[[[4-[(5-isoquinolinyloxy)methyl]phenyl]sulfonyl]methyl]-, (3R,4S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 1101041-20-6 HCAPLUS
CN 3-Furancarboxamide, tetrahydro-N-hydroxy-4-[[[4-[[(2-methyl-4-quinolinyl)oxy]methyl]phenyl]sulfonyl]methyl]-, (3R,4S)- (CA INDEX NAME)

Absolute stereochemistry.

L5 ANSWER 1 OF 3 HCAPLUS COPYRIGHT 2011 ACS on STN (Continued)



RN 1101041-21-7 HCAPLUS
CN 3-Furancarboxamide, tetrahydro-N-hydroxy-4-[[[4-(1H-indol-5-yloxy)phenyl]sulfonyl]methyl]-, (3R,4S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 1101041-22-8 HCAPLUS
CN 3-Furancarboxamide, tetrahydro-N-hydroxy-4-[[[4-[(1-methyl-1H-indol-5-yl)oxy]phenyl]sulfonyl]methyl]-, (3R,4S)- (CA INDEX NAME)

Absolute stereochemistry.

L5 ANSWER 1 OF 3 HCAPLUS COPYRIGHT 2011 ACS on STN (Continued)



RN 1101041-23-9 HCAPLUS
CN 3-Furancarboxamide, 4-[[[4-[(1-ethyl-1H-indol-5-yl)oxy]phenyl]sulfonyl]methyl]tetrahydro-N-hydroxy-, (3R,4S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 1101041-24-0 HCAPLUS
CN 3-Furancarboxamide, tetrahydro-N-hydroxy-4-[[[4-[(1H-indol-5-yloxy)methyl]phenyl]sulfonyl]methyl]-, (3R,4S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 1101041-25-1 HCAPLUS
CN 3-Furancarboxamide, tetrahydro-N-hydroxy-4-[[[4-[[[(1-methyl-1H-indol-5-yl)oxy]methyl]phenyl]sulfonyl]methyl]-, (3R,4S)- (CA INDEX NAME)

Absolute stereochemistry.

L5 ANSWER 1 OF 3 HCAPLUS COPYRIGHT 2011 ACS on STN (Continued)



RN 1101041-26-2 HCAPLUS
CN INDEX NAME NOT YET ASSICNED

Absolute stereochemistry.



RN 1101041-27-3 HCAPLUS
CN 3-Furancarboxamide, tetrahydro-N-hydroxy-4-[[[4-(1H-indol-5-ylmethoxy)phenyl]sulfonyl]methyl]-, (3R,4S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 1101041-28-4 HCAPLUS
CN 3-Furancarboxamide, tetrahydro-N-hydroxy-4-[[[4-[(1-methyl-1H-indol-5-yl)methoxy]phenyl]sulfonyl]methyl]-, (3R,4S)- (CA INDEX NAME)

Absolute stereochemistry.

L5 ANSWER 1 OF 3 HCAPLUS COPYRIGHT 2011 ACS on STN (Continued)



RN 1101041-29-5 HCAPLUS
CN 3-Furancarboxamide, 4-[[[4-[(1-ethyl-1H-indol-5-yl)methoxy]phenyl]sulfonyl]methyl]tetrahydro-N-hydroxy-, (3R,4S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 1101041-30-8 HCAPLUS
CN INDEX NAME NOT YET ASSICNED

Absolute stereochemistry.



RN 1101041-31-9 HCAPLUS
CN 3-Furancarboxamide, 4-[[[4-[2-(1H-benzimidazol-1-yl)ethyl]phenyl]sulfonyl]methyl]tetrahydro-N-hydroxy-, (3R,4S)- (CA INDEX NAME)

Absolute stereochemistry.

L5 ANSWER 1 OF 3 HCAPLUS COPYRIGHT 2011 ACS on STN (Continued)



RN 1101041-32-0 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.



RN 1101041-33-1 HCAPLUS
CN 3-Furancarboxamide, 4-[[[4-[(2,5-dimethyl-4-thiazolyl)methoxy]phenyl]sulfonyl]methyl]tetrahydro-N-hydroxy-, (3R,4S)-(CA INDEX NAME)

Absolute stereochemistry.



RN 1101041-34-2 HCAPLUS
CN 3-Furancarboxamide, 4-[[[4-[2-(1H-benzotriazol-1-yl)ethyl]phenyl]sulfonyl]methyl]tetrahydro-N-hydroxy-, (3R,4S)- (CA INDEX NAME)

L5 ANSWER 1 OF 3 HCAPLUS COPYRIGHT 2011 ACS on STN (Continued)

RN 1101041-37-5 HCAPLUS
CN 3-Furancarboxamide, tetrahydro-N-hydroxy-4-[[[4-[[2-(1-methylethyl)-4-thiazolyl]methoxy]phenyl]sulfonyl]methyl]-, (3R,4S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 1101041-38-6 HCAPLUS
CN 3-Furancarboxamide, tetrahydro-N-hydroxy-4-[[[4-[[2-(1-methylethyl)-5-thiazolyl]methoxy]phenyl]sulfonyl]methyl]-, (3R,4S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 1101041-39-7 HCAPLUS
CN 3-Furancarboxamide, 4-[[[4-[(3,5-dimethyl-4-isoxazolyl)methoxy]phenyl]sulfonyl]methyl]tetrahydro-N-hydroxy-, (3R,4S)-
(CA INDEX NAME)

Absolute stereochemistry.



RN 1101041-40-0 HCAPLUS
CN 3-Furancarboxamide, 4-[[[4-(2-butyn-1-yloxy)phenyl]sulfonyl]methyl]tetrahydro-N-hydroxy-, (3R,4S)- (CA INDEX NAME)

L5 ANSWER 1 OF 3 HCAPLUS COPYRIGHT 2011 ACS on STN (Continued)

Absolute stereochemistry.



RN 1101041-35-3 HCAPLUS
CN 3-Furancarboxamide, 4-[[[4-[(4,5-dimethyl-2-thiazolyl)methoxy]phenyl]sulfonyl]methyl]tetrahydro-N-hydroxy-, (3R,4S)-(CA INDEX NAME)

Absolute stereochemistry.



RN 1101041-36-4 HCAPLUS
CN 3-Furancarboxamide, 4-[[[4-[(2,4-dimethyl-5-thiazolyl)methoxy]phenyl]sulfonyl]methyl]tetrahydro-N-hydroxy-, (3R,4S)-(CA INDEX NAME)

Absolute stereochemistry.



L5 ANSWER 1 OF 3 HCAPLUS COPYRIGHT 2011 ACS on STN (Continued)

Absolute stereochemistry.



RN 1101041-41-1 HCAPLUS
CN 3-Furancarboxamide, tetrahydro-N-hydroxy-4-[[[4-(2-pentyn-1-yloxy)phenyl]sulfonyl]methyl]-, (3R,4S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 1101041-84-2 HCAPLUS
CN 3-Furancarboxamide, tetrahydro-N-hydroxy-4-[(phenylsulfonyl)methyl]-, (3R,4S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 1101041-85-3 HCAPLUS
CN 3-Furancarboxamide, tetrahydro-N-hydroxy-4-[[(4-methylphenyl)sulfonyl]methyl]-, (3R,4S)- (CA INDEX NAME)

Absolute stereochemistry.

L5 ANSWER 1 OF 3 HCAPLUS COPYRIGHT 2011 ACS on STN (Continued)



RN 1101041-86-4 HCAPLUS
CN 3-Furancarboxamide, tetrahydro-N-hydroxy-4-[[(4-methoxyphenyl)sulfonyl]methyl]-, (3R,4S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 1101041-87-5 HCAPLUS
CN 3-Furancarboxamide, 4-[[(4-ethoxyphenyl)sulfonyl]methyl]tetrahydro-N-hydroxy-, (3R,4S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 1101041-88-6 HCAPLUS
CN 3-Furancarboxamide, tetrahydro-N-hydroxy-4-[[(4-propoxyphenyl)sulfonyl]methyl]-, (3R,4S)- (CA INDEX NAME)

Absolute stereochemistry.

L5 ANSWER 1 OF 3 HCAPLUS COPYRIGHT 2011 ACS on STN (Continued)



RN 1101041-89-7 HCAPLUS
CN 3-Furancarboxamide, tetrahydro-N-hydroxy-4-[[[4-(1-methylethoxy)phenyl]sulfonyl]methyl]-, (3R,4S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 1101041-90-0 HCAPLUS
CN 3-Furancarboxamide, tetrahydro-N-hydroxy-4-[[[4-(2-methylpropoxy)phenyl]sulfonyl]methyl]-, (3R,4S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 1101041-91-1 HCAPLUS
CN 3-Furancarboxamide, 4-[[[4-(1,1-dimethylethoxy)phenyl]sulfonyl]methyl]tetrahydro-N-hydroxy-, (3R,4S)- (CA
INDEX NAME)

Absolute stereochemistry.

L5 ANSWER 1 OF 3 HCAPLUS COPYRIGHT 2011 ACS on STN (Continued)



RN 1101041-92-2 HCAPLUS
CN 3-Furancarboxamide, 4-[[[4-(cyclopropyloxy)phenyl]sulfonyl]methyl]tetrahydro-N-hydroxy-, (3R,4S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 1101041-93-3 HCAPLUS
CN 3-Furancarboxamide, 4-[[[4-(cyclobutyloxy)phenyl]sulfonyl]methyl]tetrahydro-N-hydroxy-, (3R,4S)- (CA
INDEX NAME)

Absolute stereochemistry.



RN 1101041-94-4 HCAPLUS
CN 3-Furancarboxamide, 4-[[[4-(cyclopentyloxy)phenyl]sulfonyl]methyl]tetrahydro-N-hydroxy-, (3R,4S)- (CA INDEX NAME)

Absolute stereochemistry.

L5 ANSWER 1 OF 3 HCAPLUS COPYRIGHT 2011 ACS on STN (Continued)



RN 1101041-95-5 HCAPLUS
CN 3-Furancarboxamide, 4-[[[4-(cyclohexyloxy)phenyl]sulfonyl]methyl]tetrahydro-N-hydroxy-, (3R,4S)- (CA
INDEX NAME)

Absolute stereochemistry.



RN 1101041-96-6 HCAPLUS
CN 3-Furancarboxamide, tetrahydro-N-hydroxy-4-[[(4-phenoxyphenyl)sulfonyl]methyl]-, (3R,4S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 1101041-97-7 HCAPLUS
CN 3-Furancarboxamide, 4-[[[4-(3,5-dimethylphenoxy)phenyl]sulfonyl]methyl]tetrahydro-N-hydroxy-, (3R,4S)- (CA INDEX NAME)

Absolute stereochemistry.

L5 ANSWER 1 OF 3 HCAPLUS COPYRIGHT 2011 ACS on STN (Continued)



RN 1101041-98-8 HCAPLUS
CN 3-Furancarboxamide, 4-[[[4-(3,5-dichlorophenoxy)phenyl]sulfonyl]methyl]tetrahydro-N-hydroxy-, (3R,4S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 1101041-99-9 HCAPLUS
CN 3-Furancarboxamide, tetrahydro-N-hydroxy-4-[[[4-(3-methylphenoxy)phenyl]sulfonyl]methyl]-, (3R,4S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 1101042-00-5 HCAPLUS
CN 3-Furancarboxamide, 4-[[[4-(3-chlorophenoxy)phenyl]sulfonyl]methyl]tetrahydro-N-hydroxy-, (3R,4S)- (CA INDEX NAME)

Absolute stereochemistry.

L5 ANSWER 1 OF 3 HCAPLUS COPYRIGHT 2011 ACS on STN (Continued)



RN 1101042-04-9 HCAPLUS
CN 3-Furancarboxamide, 4-[[[4-[(2,6-dimethyl-4-pyridinyl)oxy]phenyl]sulfonyl]methyl]tetrahydro-N-hydroxy-, (3R,4S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 1101042-05-0 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.



RN 1101042-06-1 HCAPLUS
CN 3-Furancarboxamide, tetrahydro-N-hydroxy-4-[[[4-(5-quinolinyloxy)phenyl]sulfonyl]methyl]-, (3R,4S)- (CA INDEX NAME)

Absolute stereochemistry.

L5 ANSWER 1 OF 3 HCAPLUS COPYRIGHT 2011 ACS on STN (Continued)



RN 1101042-01-6 HCAPLUS
CN 3-Furancarboxamide, tetrahydro-N-hydroxy-4-[[[4-(4-methylphenoxy)phenyl]sulfonyl]methyl]-, (3R,4S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 1101042-02-7 HCAPLUS
CN 3-Furancarboxamide, 4-[[[4-(4-chlorophenoxy)phenyl]sulfonyl]methyl]tetrahydro-N-hydroxy-, (3R,4S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 1101042-03-8 HCAPLUS
CN 3-Furancarboxamide, tetrahydro-N-hydroxy-4-[[[4-(4-pyridinyloxy)phenyl]sulfonyl]methyl]-, (3R,4S)- (CA INDEX NAME)

Absolute stereochemistry.

L5 ANSWER 1 OF 3 HCAPLUS COPYRIGHT 2011 ACS on STN (Continued)



RN 1101042-07-2 HCAPLUS
CN 3-Furancarboxamide, tetrahydro-N-hydroxy-4-[[[4-(6-quinolinyloxy)phenyl]sulfonyl]methyl]-, (3R,4S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 1101042-08-3 HCAPLUS
CN 3-Furancarboxamide, tetrahydro-N-hydroxy-4-[[[4-(5-isoquinolinyloxy)phenyl]sulfonyl]methyl]-, (3R,4S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 1101042-09-4 HCAPLUS
CN 3-Furancarboxamide, tetrahydro-N-hydroxy-4-[[[4-[(2-methyl-4-quinolinyl)oxy]phenyl]sulfonyl]methyl]-, (3R,4S)- (CA INDEX NAME)

Absolute stereochemistry.

L5 ANSWER 1 OF 3 HCAPLUS COPYRIGHT 2011 ACS on STN (Continued)



RN 1101042-10-7 HCAPLUS
CN 3-Furancarboxamide, tetrahydro-N-hydroxy-4-[[[4-(phenylmethoxy)phenyl]sulfonyl]methyl]-, (3R,4S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 1101042-11-8 HCAPLUS
CN 3-Furancarboxamide, 4-[[[4-[(3,5-dimethylphenyl)methoxy]phenyl]sulfonyl]methyl]tetrahydro-N-hydroxy-, (3R,4S)- (CA INDEX NAME)

Absolute stereochemistry.



L5 ANSWER 1 OF 3 HCAPLUS COPYRIGHT 2011 ACS on STN (Continued)



RN 1101042-15-2 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.



RN 1101042-16-3 HCAPLUS
CN 3-Furancarboxamide, tetrahydro-N-hydroxy-4-[[[4-(2-pyridinylmethoxy)phenyl]sulfonyl]methyl]-, (3R,4S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 1101042-17-4 HCAPLUS
CN 3-Furancarboxamide, tetrahydro-N-hydroxy-4-[[[4-(3-pyridinylmethoxy)phenyl]sulfonyl]methyl]-, (3R,4S)- (CA INDEX NAME)

L5 ANSWER 1 OF 3 HCAPLUS COPYRIGHT 2011 ACS on STN (Continued)

RN 1101042-12-9 HCAPLUS
CN 3-Furancarboxamide, 4-[[[4-[(3,5-dichlorophenyl)methoxy]phenyl]sulfonyl]methyl]tetrahydro-N-hydroxy-, (3R,4S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 1101042-13-0 HCAPLUS
CN 3-Furancarboxamide, 4-[[[4-[(3,5-dimethoxyphenyl)methoxy]phenyl]sulfonyl]methyl]tetrahydro-N-hydroxy-, (3R,4S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 1101042-14-1 HCAPLUS
CN 3-Furancarboxamide, 4-[[[4-[(3,5-dibromophenyl)methoxy]phenyl]sulfonyl]methyl]tetrahydro-N-hydroxy-, (3R,4S)- (CA INDEX NAME)

Absolute stereochemistry.

L5 ANSWER 1 OF 3 HCAPLUS COPYRIGHT 2011 ACS on STN (Continued)

Absolute stereochemistry.



RN 1101042-18-5 HCAPLUS
CN 3-Furancarboxamide, tetrahydro-N-hydroxy-4-[[[4-(4-pyridinylmethoxy)phenyl]sulfonyl]methyl]-, (3R,4S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 1101042-19-6 HCAPLUS
CN 3-Furancarboxamide, 4-[[[4-[(2,6-dimethyl-4-pyridinyl)methoxy]phenyl]sulfonyl]methyl]tetrahydro-N-hydroxy-, (3R,4S)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 1101042-20-9 HCAPLUS

L5 ANSWER 1 OF 3 HCAPLUS COPYRIGHT 2011 ACS on STN (Continued)
CN 3-Furancarboxamide, 4-[[[4-[(2-chloro-6-methyl-4-pyridinyl)methoxy]phenyl]sulfonyl]methyl]tetrahydro-N-hydroxy-, (3R,4S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 1101042-21-0 HCAPLUS
CN 3-Furancarboxamide, 4-[[[4-[(2-chloro-6-methoxy-4-pyridinyl)methoxy]phenyl]sulfonyl]methyl]tetrahydro-N-hydroxy-, (3R,4S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 1101042-22-1 HCAPLUS
CN 3-Furancarboxamide, tetrahydro-N-hydroxy-4-[[[4-(4-quinolinylmethoxy)phenyl]sulfonyl]methyl]-, (3R,4S)- (CA INDEX NAME)

Absolute stereochemistry.

L5 ANSWER 1 OF 3 HCAPLUS COPYRIGHT 2011 ACS on STN (Continued)

RN 1101042-24-3 HCAPLUS
CN 3-Furancarboxamide, tetrahydro-N-hydroxy-4-[[[4-(6-quinolinylmethoxy)phenyl]sulfonyl]methyl]-, (3R,4S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 1101042-25-4 HCAPLUS
CN 3-Furancarboxamide, tetrahydro-N-hydroxy-4-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]sulfonyl]methyl]-, (3R,4S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 1101042-26-5 HCAPLUS
CN 3-Furancarboxamide, tetrahydro-N-hydroxy-4-[[[4-[(2-methoxy-4-quinolinyl)methoxy]phenyl]sulfonyl]methyl]-, (3R,4S)- (CA INDEX NAME)

Absolute stereochemistry.

L5 ANSWER 1 OF 3 HCAPLUS COPYRIGHT 2011 ACS on STN (Continued)



RN 1101042-23-2 HCAPLUS
CN 3-Furancarboxamide, tetrahydro-N-hydroxy-4-[[[4-(5-quinolinylmethoxy)phenyl]sulfonyl]methyl]-, (3R,4S)- (CA INDEX NAME)

Absolute stereochemistry.



L5 ANSWER 1 OF 3 HCAPLUS COPYRIGHT 2011 ACS on STN (Continued)



RN 1101042-27-6 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.



RN 1101042-28-7 HCAPLUS
CN 3-Furancarboxamide, tetrahydro-N-hydroxy-4-[[[4-[2-(4-quinolinyl)ethoxy]phenyl]sulfonyl]methyl]-, (3R,4S)- (CA INDEX NAME)

L5 ANSWER 1 OF 3 HCAPLUS COPYRIGHT 2011 ACS on STN (Continued)
Absolute stereochemistry.



RN 1101042-29-8 HCAPLUS
CN 3-Furancarboxamide, tetrahydro-N-hydroxy-4-[[[4-[2-(5-quinolinyl)ethoxy]phenyl]sulfonyl]methyl]-, (3R,4S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 1101042-30-1 HCAPLUS
CN 3-Furancarboxamide, tetrahydro-N-hydroxy-4-[[[4-[2-(6-quinolinyl)ethoxy]phenyl]sulfonyl]methyl]-, (3R,4S)- (CA INDEX NAME)

Absolute stereochemistry.

L5 ANSWER 1 OF 3 HCAPLUS COPYRIGHT 2011 ACS on STN (Continued)



RN 1101042-33-4 HCAPLUS
CN 3-Furancarboxamide, tetrahydro-N-hydroxy-4-[[[4-[2-(2-methoxy-4-quinolinyl)ethoxy]phenyl]sulfonyl]methyl]-, (3R,4S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 1101042-34-5 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.

L5 ANSWER 1 OF 3 HCAPLUS COPYRIGHT 2011 ACS on STN (Continued)



RN 1101042-31-2 HCAPLUS
CN 3-Furancarboxamide, tetrahydro-N-hydroxy-4-[[[4-[2-(5-isoquinolinyl)ethoxy]phenyl]sulfonyl]methyl]-, (3R,4S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 1101042-32-3 HCAPLUS
CN 3-Furancarboxamide, tetrahydro-N-hydroxy-4-[[[4-[2-(2-methyl-4-quinolinyl)ethoxy]phenyl]sulfonyl]methyl]-, (3R,4S)- (CA INDEX NAME)

Absolute stereochemistry.

L5 ANSWER 1 OF 3 HCAPLUS COPYRIGHT 2011 ACS on STN (Continued)



RN 1101042-35-6 HCAPLUS
CN 3-Furancarboxamide, 4-[[[4-[(3,5-dimethylphenoxy)methyl]phenyl]sulfonyl]methyl]tetrahydro-N-hydroxy-, (3R,4S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 1101042-36-7 HCAPLUS
CN 3-Furancarboxamide, tetrahydro-N-hydroxy-4-[[[4-(phenoxymethyl)phenyl]sulfonyl]methyl]-, (3R,4S)- (CA INDEX NAME)

Absolute stereochemistry.



L5 ANSWER 1 OF 3 HCAPLUS COPYRIGHT 2011 ACS on STN (Continued)
RN 1101042-37-8 HCAPLUS
CN 3-Furancarboxamide, 4-[[[4-[(3,5-dichlorophenoxy)methyl]phenyl]sulfonyl]methyl]tetrahydro-N-hydroxy-, (3R,4S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 1101042-38-9 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.



RN 1101042-39-0 HCAPLUS
CN 3-Furancarboxamide, tetrahydro-N-hydroxy-4-[[[4-[(4-pyridinyloxy)methyl]phenyl]sulfonyl]methyl]-, (3R,4S)- (CA INDEX NAME)

Absolute stereochemistry.

L5 ANSWER 1 OF 3 HCAPLUS COPYRIGHT 2011 ACS on STN (Continued)



RN 1101042-40-3 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.



RN 1101043-60-0 HCAPLUS
CN 3-Pyrrolidinecarboxamide, N-hydroxy-4-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]sulfonyl]methyl]-1-phenyl-, (3R,4S)- (CA INDEX NAME)

Absolute stereochemistry.

L5 ANSWER 1 OF 3 HCAPLUS COPYRIGHT 2011 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A

RN 1101043-61-1 HCAPLUS
CN 3-Pyrrolidinecarboxamide, N-hydroxy-4-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]sulfonyl]methyl]-1-(2-pyridinyl)-, (3R,4S)- (CA INDEX NAME)

Absolute stereochemistry.

L5 ANSWER 1 OF 3 HCAPLUS COPYRIGHT 2011 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A



RN 1101043-62-2 HCAPLUS
CN 3-Pyrrolidinecarboxamide, N-hydroxy-4-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]sulfonyl]methyl]-1-(3-pyridinyl)-, (3R,4S)- (CA INDEX NAME)

Absolute stereochemistry.

L5 ANSWER 1 OF 3 HCAPLUS COPYRIGHT 2011 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A



RN 1101043-63-3 HCAPLUS
CN 3-Pyrrolidinecarboxamide, N-hydroxy-4-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]sulfonyl]methyl]-1-(4-pyridinyl)-, (3R,4S)-(CA INDEX NAME)

Absolute stereochemistry.

L5 ANSWER 1 OF 3 HCAPLUS COPYRIGHT 2011 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A



RN 1101043-64-4 HCAPLUS
CN 3-Pyrrolidinecarboxamide, 1-acetyl-N-hydroxy-4-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]sulfonyl]methyl]-, (3R,4S)- (CA INDEX NAME)

Absolute stereochemistry.

L5 ANSWER 1 OF 3 HCAPLUS COPYRIGHT 2011 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A



RN 1101043-65-5 HCAPLUS
CN 3-Pyrrolidinecarboxamide, N-hydroxy-4-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]sulfonyl]methyl]-1-(1-oxopropyl)-, (3R,4S)-(CA INDEX NAME)

Absolute stereochemistry.

L5 ANSWER 1 OF 3 HCAPLUS COPYRIGHT 2011 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A



RN 1101043-66-6 HCAPLUS
CN 3-Pyrrolidinecarboxamide, N-hydroxy-4-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]sulfonyl]methyl]-1-(1-oxobutyl)-, (3R,4S)- (CA INDEX NAME)

Absolute stereochemistry.

L5 ANSWER 1 OF 3 HCAPLUS COPYRIGHT 2011 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A

RN 1101043-67-7 HCAPLUS
CN 3-Pyrrolidinecarboxamide, N-hydroxy-1-(2-methyl-1-oxopropyl)-4-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]sulfonyl]methyl]-, (3R,4S)- (CA INDEX NAME)

Absolute stereochemistry.

L5 ANSWER 1 OF 3 HCAPLUS COPYRIGHT 2011 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A



RN 1101043-68-8 HCAPLUS
CN 3-Pyrrolidinecarboxamide, 1-(2,2-dimethyl-1-oxopropyl)-N-hydroxy-4-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]sulfonyl]methyl]-, (3R,4S)- (CA INDEX NAME)

Absolute stereochemistry.

L5 ANSWER 1 OF 3 HCAPLUS COPYRIGHT 2011 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A



RN 1101043-69-9 HCAPLUS
CN 3-Pyrrolidinecarboxamide, N-hydroxy-4-[[[4-[(2-methyl-4-quinolinyl]methoxy]phenyl]sulfonyl]methyl]-1-(2-pyridinylcarbonyl)-, (3R,4S)- (CA INDEX NAME)

Absolute stereochemistry.

L5 ANSWER 1 OF 3 HCAPLUS COPYRIGHT 2011 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A



RN 1101043-70-2 HCAPLUS
CN 3-Pyrrolidinecarboxamide, N-hydroxy-4-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]sulfonyl]methyl]-1-(3-pyridinylcarbonyl)-, (3R,4S)- (CA INDEX NAME)

Absolute stereochemistry.

L5 ANSWER 1 OF 3 HCAPLUS COPYRIGHT 2011 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A



RN 1101043-71-3 HCAPLUS
CN 3-Pyrrolidinecarboxamide, N-hydroxy-4-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]sulfonyl]methyl]-1-(4-pyridinylcarbonyl)-, (3R,4S)- (CA INDEX NAME)

Absolute stereochemistry.

L5 ANSWER 1 OF 3 HCAPLUS COPYRIGHT 2011 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A



RN 1101043-72-4 HCAPLUS
CN 3-Pyrrolidinecarboxamide, N-hydroxy-4-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]sulfonyl]methyl]-1-(methylsulfonyl)-, (3R,4S)- (CA INDEX NAME)

Absolute stereochemistry.

L5 ANSWER 1 OF 3 HCAPLUS COPYRIGHT 2011 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A



RN 1101043-73-5 HCAPLUS
CN 3-Pyrrolidinecarboxamide, N-hydroxy-4-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]sulfonyl]methyl]-1-(phenylsulfonyl)-, (3R,4S)- (CA INDEX NAME)

Absolute stereochemistry.

L5 ANSWER 1 OF 3 HCAPLUS COPYRIGHT 2011 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A



RN 1101043-74-6 HCAPLUS
CN 3-Pyrrolidinecarboxamide, N-hydroxy-4-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]sulfonyl]methyl]-1-(2-pyridinylsulfonyl)-, (3R,4S)- (CA INDEX NAME)

Absolute stereochemistry.

L5 ANSWER 1 OF 3 HCAPLUS COPYRIGHT 2011 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A



RN 1101043-75-7 HCAPLUS
CN 3-Pyrrolidinecarboxamide, N-hydroxy-4-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]sulfonyl]methyl]-1-(3-pyridinylsulfonyl)-, (3R,4S)- (CA INDEX NAME)

Absolute stereochemistry.

L5 ANSWER 1 OF 3 HCAPLUS COPYRIGHT 2011 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A



RN 1101043-76-8 HCAPLUS
CN 3-Pyrrolidinecarboxamide, N-hydroxy-4-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]sulfonyl]methyl]-1-(4-pyridinylsulfonyl)-, (3R,4S)- (CA INDEX NAME)

Absolute stereochemistry.

L5 ANSWER 1 OF 3 HCAPLUS COPYRIGHT 2011 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A



RN 1101043-77-9 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.

L5 ANSWER 1 OF 3 HCAPLUS COPYRIGHT 2011 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A



RN 1101043-78-0 HCAPLUS
CN 1-Pyrrolidinecarboxylic acid, 3-[(hydroxyamino)carbonyl]-4-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]sulfonyl]methyl]-, propyl ester, (3R,4S)- (CA INDEX NAME)

Absolute stereochemistry.

L5 ANSWER 1 OF 3 HCAPLUS COPYRIGHT 2011 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A



RN 1101043-79-1 HCAPLUS
CN 1-Pyrrolidinecarboxylic acid,
3-[(hydroxyamino)carbonyl]-4-[[[4-[(2-methyl-
4-quinolinyl)methoxy]phenyl]sulfonyl]methyl]-, 1-methylethyl ester,
(3R,4S)- (CA INDEX NAME)

Absolute stereochemistry.

L5 ANSWER 1 OF 3 HCAPLUS COPYRIGHT 2011 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A



RN 1101043-80-4 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.

L5 ANSWER 1 OF 3 HCAPLUS COPYRIGHT 2011 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A



RN 1101043-81-5 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.

L5 ANSWER 1 OF 3 HCAPLUS COPYRIGHT 2011 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A



RN 1101043-82-6 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.

L5 ANSWER 1 OF 3 HCAPLUS COPYRIGHT 2011 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A



RN 1101043-83-7 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.

L5 ANSWER 1 OF 3 HCAPLUS COPYRIGHT 2011 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A



RN 1101043-84-8 HCAPLUS
CN INDEX NAME NOT YET ASSIGNED

Absolute stereochemistry.

L5 ANSWER 1 OF 3 HCAPLUS COPYRIGHT 2011 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A



RN 1101044-58-9 HCAPLUS
CN 3-Pyrrolidinecarboxamide, 1-ethyl-N-hydroxy-4-[[[4-[(2-methyl-4-quinolinyl]methoxy]phenyl]sulfonyl]methyl]-, (3R,4S)- (CA INDEX NAME)

Absolute stereochemistry.

L5 ANSWER 1 OF 3 HCAPLUS COPYRIGHT 2011 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A

RN 1101044-59-0 HCAPLUS
CN 3-Pyrrolidinecarboxamide, N-hydroxy-4-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]sulfonyl]methyl]-1-propyl-, (3R,4S)- (CA INDEX NAME)

Absolute stereochemistry.

L5 ANSWER 1 OF 3 HCAPLUS COPYRIGHT 2011 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A

RN 1101044-60-3 HCAPLUS
CN 3-Pyrrolidinecarboxamide, 1-butyl-N-hydroxy-4-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]sulfonyl]methyl]-, (3R,4S)- (CA INDEX NAME)

Absolute stereochemistry.

L5 ANSWER 1 OF 3 HCAPLUS COPYRIGHT 2011 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A

RN 1101044-61-4 HCAPLUS
CN 3-Pyrrolidinecarboxamide, N-hydroxy-1-(2-methylpropyl)-4-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]sulfonyl]methyl]-, (3R,4S)- (CA INDEX NAME)

Absolute stereochemistry.

L5 ANSWER 1 OF 3 HCAPLUS COPYRIGHT 2011 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A

RN 1101044-62-5 HCAPLUS
CN 3-Pyrrolidinecarboxamide, 1-cyclobutyl-N-hydroxy-4-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]sulfonyl]methyl]-, (3R,4S)- (CA INDEX NAME)

Absolute stereochemistry.

L5 ANSWER 1 OF 3 HCAPLUS COPYRIGHT 2011 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A



RN 1101044-63-6 HCAPLUS
CN 3-Pyrrolidinecarboxamide, 1-cyclohexyl-N-hydroxy-4-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]sulfonyl]methyl]-, (3R,4S)- (CA INDEX NAME)

Absolute stereochemistry.

L5 ANSWER 1 OF 3 HCAPLUS COPYRIGHT 2011 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A

RN 1101044-64-7 HCAPLUS
CN 3-Pyrrolidinecarboxamide, 1-cyclopentyl-N-hydroxy-4-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]sulfonyl]methyl]-, (3R,4S)- (CA INDEX NAME)

Absolute stereochemistry.

L5 ANSWER 1 OF 3 HCAPLUS COPYRIGHT 2011 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A



OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD (1 CITINGS)
REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L5 ANSWER 1 OF 3 HCAPLUS COPYRIGHT 2011 ACS on STN (Continued)

PAGE 1-A



PAGE 2-A



RN 1101044-65-8 HCAPLUS
CN 3-Pyrrolidinecarboxamide, N-hydroxy-4-[[[4-[(2-methyl-4-quinolinyl)methoxy]phenyl]sulfonyl]methyl]-1-(2-propen-1-yl)-, (3R,4S)- (CA INDEX NAME)

Absolute stereochemistry.

L5 ANSWER 2 OF 3 HCAPLUS COPYRIGHT 2011 ACS on STN
ACCESSION NUMBER: 2001:876610 HCAPLUS
DOCUMENT NUMBER: 136:19953
TITLE: Preparation of alkynyl aryl sulfonamide hydroxamic acids as TNF-α converting enzyme inhibitors.
INVENTOR(S): Levin, Jeremy I.; Chen, James M.; Zask, Arie
PATENT ASSIGNEE(S): American Cyanamid Company, USA
SOURCE: U.S., 21 pp.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6326516	B1	20011204	US 2000-492980	20000127

<--
PRIORITY APPLN. INFO.: US 1999-155250P P 19990127

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
OTHER SOURCE(S): MARPAT 136:19953
AB R8C.tplbond.CCR6R7ZYXNR5CHR11CHR12CONHOH, R8C.tplbond.CCR6R7ZYXNR5CR11:CR12CONHOH [X = SO2, P(O)R10; Y = heteroaryl, Ph, naphthyl; Z = O, NH, CH2, S; R5 = H, alkyl; R6, R7 = H, Me; R8 = H, alkyl, alkenyl, alkynyl, cycloalkyl, heteroaryl, Ph, etc.; R10 = alkyl, cycloalkyl, Ph, heteroaryl; R11, R12 = H, alkyl, cycloalkyl, heteroaryl, Ph; R11R12 = atoms to form (fused) (unsatd.) ring; with provisos], were prepared Thus, (1R,2S)-2-[[[4-(2-butynyloxy)phenyl]sulfonyl](methyl)amino]-N-hydroxycyclopentanecarboxamide (general preparation given) inhibited TNF-α converting enzyme (TACE) with IC50 = 14 nM.
IT 376630-57-8P, (1R,2S)-2-[[[4-(2-Butynyloxy)phenyl]sulfonyl]amino]-N-hydroxycyclopentanecarboxamide
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of alkynyl aryl sulfonamide hydroxamic acids as TNF-α converting enzyme inhibitors)
RN 376630-57-8 HCAPLUS
CN Cyclopentanecarboxamide, 2-[[[4-(2-butyn-1-yloxy)phenyl]sulfonyl]amino]-N-hydroxy-, (1R,2S)- (CA INDEX NAME)

Absolute stereochemistry.



OS.CITING REF COUNT: 7 THERE ARE 7 CAPLUS RECORDS THAT CITE THIS RECORD

L5 ANSWER 2 OF 3 HCAPLUS COPYRIGHT 2011 ACS on STN (Continued)
(7 CITINGS)
REFERENCE COUNT: 73 THERE ARE 73 CITED REFERENCES AVAILABLE FOR THIS
RECORD. ALL CITATIONS AVAILABLE IN THE RE
FORMAT

L5 ANSWER 3 OF 3 HCAPLUS COPYRIGHT 2011 ACS on STN
ACCESSION NUMBER: 2000:535104 HCAPLUS
DOCUMENT NUMBER: 133:150361
TITLE: Preparation of alkynyloxyphenylsulfonylaminoalkylhydroxamic acids and related compounds as TNF-α converting enzyme (TACE) inhibitors.
INVENTOR(S): Levin, Jeremy Ian; Chen, James Ming; Zask, Arie
PATENT ASSIGNEE(S): American Cyanamid Company, USA
SOURCE: PCT Int. Appl., 58 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000044711	A1	20000803	WO 2000-US1865	20000127
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2356345	A1	20000803	CA 2000-2356345	20000127
EP 1147078	A1	20011024	EP 2000-904570	20000127
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
BR 2000007754	A	20011113	BR 2000-7754	20000127
HU 2002000605	A2	20020729	HU 2002-605	20000127
HU 2002000605	A3	20050530		
JP 2002535383	T	20021022	JP 2000-595968	20000127
NZ 512025	A	20030829	NZ 2000-512025	20000127
AU 769410	B2	20040129	AU 2000-26306	20000127
ZA 2001004508	A	20020902	ZA 2001-4508	20010531
NO 2001003639	A	20010724	NO 2001-3639	20010724
MX 2001007465	A	20011203	MX 2001-7465	20010724

PRIORITY APPLN. INFO.: US 1999-239083 A 19990127
WO 2000-US1865 W 20000127

L5 ANSWER 3 OF 3 HCAPLUS COPYRIGHT 2011 ACS on STN (Continued)
OTHER SOURCE(S): MARPAT 133:150361
GI



I

AB Title compds. (I; X = SO2, POR10; Y = 5-10 membered heteroaryl, Ph, naphthyl; Z = O, NH, CH2, S; R5 = H, alkyl; R6, R7 = H, Me; R8 = H, alkyl, alkenyl, alkynyl, cycloalkyl, heteroaryl, heterocycloalkyl, Ph; R9 = H, alkyl, cycloalkyl, Ph; R10 = alkyl, cycloalkyl, Ph, heteroaryl; R11, R12 = H, alkyl, cycloalkyl, heteroaryl, heterocycloalkyl; R11R12 = atoms to form 5-10 membered mono- or bicyclic (heterocyclic) ring, Ph, naphthyl; dotted line = optional double bond), were prepared Thus, (1R,2S)-2-[[[4-(2-butynyloxy)phenyl]sulfonyl]methylamino]-N-hydroxycyclopentanecarboxamide [preparation from cis-2-amino-1-cyclopentanecarboxylic acid and 4-(2-butynyloxy)phenylsulfonyl chloride given] inhibited TACE with IC50 = 14 nM.
IT 287096-61-1P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of alkynyloxyphenylsulfonylaminoalkylhydroxamic acids and related compds. as TNF-α converting enzyme inhibitors)
RN 287096-61-1 HCAPLUS
CN Cyclopentanecarboxamide, 2-[[[4-(2-butyn-1-yloxy)phenyl]sulfonyl]amino]-N-hydroxy-, (1R,2S)-rel- (CA INDEX NAME)

Relative stereochemistry.



OS.CITING REF COUNT: 4 THERE ARE 4 CAPLUS RECORDS THAT CITE THIS RECORD
(4 CITINGS)
REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE
FORMAT

=> d l4 ibib abs tot

L4 ANSWER 1 OF 5 HCAPLUS COPYRIGHT 2011 ACS on STN
ACCESSION NUMBER: 2008:1088521 HCAPLUS
DOCUMENT NUMBER: 149:513677
TITLE: Development of a Suitable Process for the Preparation of a TNF-α Converting Enzyme Inhibitor, WAY-281418
AUTHOR(S): Wang, Youchu; Papamichelakis, Maria; Chew, Warren; Sellstedt, John; Noureldin, Razzak; Tadayon, Sam; Daigneault, Sylvain
CORPORATE SOURCE: Chemical Development, Wyeth Research, Saint-Laurent, QC, H4R 1J6, Can.
SOURCE: Organic Process Research & Development (2008), 12(6), 1253-1260
CODEN: OPRDFK; ISSN: 1083-6160
PUBLISHER: American Chemical Society
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 149:513677
GI



I

II



III

AB A suitable process for the preparation of kilogram quantities of a TNF-α converting enzyme (TACE) inhibitor (WAY-281418) was developed using isatin as starting material and an efficient coupling step for the formation of sulfonamide I in a 15% overall yield. Process preparation of (+)-(1S,2R)-2-aminocyclopentane-1-carboxylic acid (II, (+)-cispentacin), a chiral component for WAY-281418, was successfully scaled up via an asym. hydrogenation reaction. Crystallization allowed the isolation of all intermediates and the final product III.

L4 ANSWER 1 OF 5 HCAPLUS COPYRIGHT 2011 ACS on STN (Continued)
REFERENCE COUNT: 17 THERE ARE 17 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 2 OF 5 HCAPLUS COPYRIGHT 2011 ACS on STN
ACCESSION NUMBER: 2006:979177 HCAPLUS
DOCUMENT NUMBER: 145:356664
TITLE: Preparation of β-sulfonamide hydroxamic acid inhibitors of TACE/matrix metalloproteinase
INVENTOR(S): Levin, Jeremy I.; Li, Zhong; Diamantidis, George; Lovering, Frank E.; Wang, Weiheng; Condon, Jeffrey S.; Lin, Yang-I.; Skotnicki, Jerauld S.; Park, Kaapjoo
PATENT ASSIGNEE(S): Wyeth, John, and Brother Ltd., USA
SOURCE: U.S. Pat. Appl. Publ., 61pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20060211730	A1	20060921	US 2006-377886	20060316
US 7595327	B2	20090929		
PRIORITY APPLN. INFO.:			US 2005-663785P P	20050321

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
OTHER SOURCE(S): CASREACT 145:356664; MARPAT 145:356664
GI



I

AB This invention provides compds. of formula I (wherein J = (un)substituted a monocyclic or bicyclic 5-8 membered cycloalkyl or heterocycloalkyl; R2 = H, (un)substituted C1-C6 alkyl, C2-C6 alkenyl or C2-C6 alkynyl; R3 = (un)substituted naphthyl or bicyclic heteroaryl; R4 and R5 = independently H, (un)substituted C1-C6 alkyl, C2-C6 alkenyl or C2-C6 alkynyl; R8 and R9 = independently H, OH, substituted amino, halo, C1-C6 alkyl, etc.; E = -C:C-, -C:N-, -N:C-, S or O; X = O, S(O)n, or substituted amino; n = 0-2) that are useful in treating diseases or disorders mediated by TNF-α, such as arthritis (rheumatoid arthritis (RA), juvenile RA, psoriatic arthritis, osteoarthritis etc.), tumor metastasis, tissue ulceration, abnormal wound healing, periodontal disease, bone disease, diabetes (insulin resistance) and HIV infection, ankylosing spondylitis, psoriasis, sepsis, multiple sclerosis, Crohn's disease, degenerative cartilage loss, asthma, idiopathic pulmonary fibrosis, vasculitis, systemic lupus erythematosus, irritable bowel syndrome, acute coronary syndrome, hepatitis C, cachexia, COPD, stroke or type 2 diabetes, and for alleviation of symptoms thereof. The invention further provides methods for use of the compds. Preparation of I is exemplified. For example, II was prepd. by reacting 3-endo-aminobicyclo[2.2.1]hept-5-ene-2-endo-carboxylic acid with 4-(2-methylquinolin-4-ylmethoxy)benzenesulfonyl chloride hydrochloride and reacting the intermediate formed with hydroxylamine. In an assay involving cleavage of pro-TNF by TACE, II had an IC50 of 1.2 nM.

L4 ANSWER 2 OF 5 HCAPLUS COPYRIGHT 2011 ACS on STN (Continued)
OS.CITING REF COUNT: 2 THERE ARE 2 CAPLUS RECORDS THAT CITE THIS RECORD (2 CITINGS)

L4 ANSWER 3 OF 5 HCAPLUS COPYRIGHT 2011 ACS on STN
ACCESSION NUMBER: 2002:539654 HCAPLUS
DOCUMENT NUMBER: 137:93692
TITLE: Preparation of (quinolinylmethoxyphenylsulfonylmethyl)-substituted pyrrolidinecarboxamides and piperidinecarboxamides as MMP, TNF, and/or aggrecanase inhibitors
INVENTOR(S): Xue, Chu-Biao; Decicco, Carl P.; He, Xiaohua
PATENT ASSIGNEE(S): Bristol-Myers Squibb Company Patent Department, USA
SOURCE: PCT Int. Appl., 133 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2002055491	A2	20020718	WO 2002-US760	20020109
WO 2002055491	A3	20030123		
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NO, NZ, OM, PH, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
CA 2434044	A1	20020718	CA 2002-2434044	20020109
AU 2002246983	A1	20020724	AU 2002-246983	20020109
US 20030087890	A1	20030508	US 2002-43541	20020109
US 6642255	B2	20031104		
EP 1355648	A2	20031029	EP 2002-714733	20020109
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR				

PRIORITY APPLN. INFO.: US 2001-260957P P 20010111
WO 2002-US760 W 20020109

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
OTHER SOURCE(S): MARPAT 137:93692
GI

L4 ANSWER 3 OF 5 HCAPLUS COPYRIGHT 2011 ACS on STN (Continued)



I



II

AB Title compds. I [wherein A = COR5, CO2H, CH2CO2H, CO2R6, CONHOH, CONHOR5, CONHOR6, N(OH)CHO, N(OH)COR5, SH, CH2SH, SONHRa, SN2H2Ra, PO3H2, or PO(OH)NHRa; ring B = 3-10 membered (hetero)cycle; Z = absent or (un)substituted (hetero)cyclyl; U = absent or O, NH, N(alkyl),, CO, CO2, OCO, CONH, NHCO, OCO2, etc. X = absent or alkylene, alkenylene, or alkynylene; Y = absent or O, NH, N(alkyl), SO0-2, or CO; Za = (un)substituted (hetero)cyclyl; Rla and Rlb = independently H, alkyl, Ph, PhCH2, CH2OR3, or (un)substituted CH2NH2; or CRlaRlb = (hetero)cyclyl; R2 = Q or (un)substituted alkylene-Q, alkenylene-Q, or alkynylene-Q, Q-substituted alkoxy(alkyl), carbamoyl(alkyl), sulfamoyl(alkyl), etc.; R2a = H, alkyl, ORa, (un)substituted CH2NH2, or SO0-2Ra; R2b = H or alkyl; Q = H or (un)substituted (hetero)cyclyl; R3 = Q1 or (un)substituted alkylene-Q1, alkenylene-Q1, or alkynylene-Q1, Q1-substituted alkoxy(alkyl), carbamoyl(alkyl), sulfamoyl(alkyl), etc.; or C(R3)2 = (un)substituted (hetero)cyclyl; Q1 = H or (un)substituted Ph, naphthyl, or heteroaryl; Ra = H, alkyl, Ph, or PhCH2; p = 0-2; R5 = (un)substituted alkyl; R6 = phenyl(alkyl), naphthyl, cycloalkyl, alkylcarbonyloxy, etc.; or pharmaceutically acceptable salt thereof] were prepared as matrix metalloprotease (MMP), tumor necrosis factor (TNF), and aggrecanase inhibitors. For example, the 3-(quinolinylmethoxyphenylsulfonylmethyl)-4-piperidinecarboxamide (3R,4S)-II•2CF3CO2H was prepared in seventeen steps starting from the reaction of N-benzyloxycarbonyl-β-alanine and benzylbromide. Key steps include the cyclization of the 5-aminopentanal intermediate and the addition of 4-mercaptophenol and 4-chloromethyl-2-methylquinoline•HCl. A number of invention compds.

L4 ANSWER 3 OF 5 HCAPLUS COPYRIGHT 2011 ACS on STN (Continued)
exhibited Ki values of ≤ 10 μM against MMP-1, 2, 3, 9, and 13. Thus, I are useful for the treatment of inflammatory disorders and thromboembolic disorder (no data).
OS.CITING REF COUNT: 1 THERE ARE 1 CAPLUS RECORDS THAT CITE THIS RECORD
(1 CITINGS)
REFERENCE COUNT: 1 THERE ARE 1 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 4 OF 5 HCAPLUS COPYRIGHT 2011 ACS on STN
ACCESSION NUMBER: 2001:876610 HCAPLUS
DOCUMENT NUMBER: 136:19953
TITLE: Preparation of alkynyl aryl sulfonamide hydroxamic acids as TNF-α converting enzyme inhibitors.
INVENTOR(S): Levin, Jeremy I.; Chen, James M.; Zask, Arie
PATENT ASSIGNEE(S): American Cyanamid Company, USA
SOURCE: U.S., 21 pp.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6326516	B1	20011204	US 2000-492980	20000127

PRIORITY APPLN. INFO.: US 1999-155250P P 19990127

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
OTHER SOURCE(S): MARPAT 136:19953
AB R8C.tplbond.CCR6R7ZYXNR5CHR11CHR12CONHOH, R8C.tplbond.CCR6R7ZYXNR5CR11:CR12CONHOH [X = SO2, P(O)R10; Y = heteroaryl, Ph, naphthyl; Z = O, NH, CH2, S; R5 = H, alkyl; R6, R7 = H, Me; R8 = H, alkyl, alkenyl, alkynyl, cycloalkyl, heteroaryl, Ph, etc.; R10 = alkyl, cycloalkyl, Ph, heteroaryl; R11, R12 = H, alkyl, cycloalkyl, heteroaryl, Ph; R11R12 = atoms to form (fused) (unsatd.) ring; with provisos], were prepared Thus, (1R,2S)-2-[[[4-(2-butynyloxy)phenyl]sulfonyl](methyl)amino]-N-hydroxycyclopentanecarboxamide (general preparation given) inhibited TNF-α converting enzyme (TACE) with IC50 = 14 nM.
OS.CITING REF COUNT: 7 THERE ARE 7 CAPLUS RECORDS THAT CITE THIS RECORD
(7 CITINGS)
REFERENCE COUNT: 73 THERE ARE 73 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L4 ANSWER 5 OF 5 HCAPLUS COPYRIGHT 2011 ACS on STN
ACCESSION NUMBER: 2000:535104 HCAPLUS
DOCUMENT NUMBER: 133:150361
TITLE: Preparation of alkynyloxyphenylsulfonylaminoalkylhydroxamic acids and related compounds as TNF-α converting enzyme (TACE) inhibitors.
INVENTOR(S): Levin, Jeremy Ian; Chen, James Ming; Zask, Arie
PATENT ASSIGNEE(S): American Cyanamid Company, USA
SOURCE: PCT Int. Appl., 58 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000044711	A1	20000803	WO 2000-US1865	20000127
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2356345	A1	20000803	CA 2000-2356345	20000127
EP 1147078	A1	20011024	EP 2000-904570	20000127
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
BR 2000007754	A	20011113	BR 2000-7754	20000127
HU 2002000605	A2	20020729	HU 2002-605	20000127
HU 2002000605	A3	20050530		
JP 2002535383	T	20021022	JP 2000-595968	20000127
NZ 512025	A	20030829	NZ 2000-512025	20000127
AU 769410	B2	20040129	AU 2000-26306	20000127
ZA 2001004508	A	20020902	ZA 2001-4508	20010531
NO 2001003639	A	20010724	NO 2001-3639	20010724
MX 2001007465	A	20011203	MX 2001-7465	20010724
PRIORITY APPLN. INFO.:			US 1999-239083 A	19990127
			WO 2000-US1865 W	20000127

OTHER SOURCE(S): MARPAT 133:150361
GI

L4 ANSWER 5 OF 5 HCAPLUS COPYRIGHT 2011 ACS on STN (Continued)



I

AB Title compds. (I; X = SO2, POR10; Y = 5-10 membered heteroaryl, Ph, naphthyl; Z = O, NH, CH2, S; R5 = H, alkyl; R6, R7 = H, Me; R8 = H, alkyl, alkenyl, alkynyl, cycloalkyl, heteroaryl, heterocycloalkyl, Ph; R9 = H, alkyl, cycloalkyl, Ph; R10 = alkyl, cycloalkyl, Ph, heteroaryl; R11, R12 = H, alkyl, cycloalkyl, heteroaryl, heterocycloalkyl; R11R12 = atoms to form 5-10 membered mono- or bicyclic (heterocyclic) ring, Ph, naphthyl; dotted line = optional double bond), were prepared Thus, (1R,2S)-2-[[[4-(2-butynyloxy)phenyl]sulfonyl]methylamino]-N-hydroxycyclopentanecarboxamide [preparation from cis-2-amino-1-cyclopentanecarboxylic acid and 4-(2-butynyloxy)phenylsulfonyl chloride given] inhibited TACE with IC50 = 14 nM.
OS.CITING REF COUNT: 4 THERE ARE 4 CAPLUS RECORDS THAT CITE THIS RECORD (4 CITINGS)
REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

```
=> FIL REGISTRY
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                         ENTRY    SESSION
FULL ESTIMATED COST                                      69.76     270.35

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)          SINCE FILE      TOTAL
                                                         ENTRY    SESSION
CA SUBSCRIBER PRICE                                      -6.96      -6.96

FILE 'REGISTRY' ENTERED AT 09:55:08 ON 22 FEB 2011
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.
COPYRIGHT (C) 2011 American Chemical Society (ACS)

Property values tagged with IC are from the ZIC/VINITI data file
provided by InfoChem.

STRUCTURE FILE UPDATES:   21 FEB 2011  HIGHEST RN 1263357-65-8
DICTIONARY FILE UPDATES:  21 FEB 2011  HIGHEST RN 1263357-65-8

New CAS Information Use Policies, enter HELP USAGETERMS for details.

TSCA INFORMATION NOW CURRENT THROUGH June 26, 2010.

  Please note that search-term pricing does apply when
  conducting SmartSELECT searches.

REGISTRY includes numerically searchable data for experimental and
predicted properties as well as tags indicating availability of
experimental property data in the original document.  For information
on property searching in REGISTRY, refer to:

http://www.cas.org/support/stngen/stndoc/properties.html

=>
Uploading C:\Program Files\Stnexp\Queries\10593748a.str
```





chain nodes :
7 8 11 12 13 14 15 16 17 18
ring nodes :
1 2 3 4 5
chain bonds :
3-14 4-7 7-8 8-11 8-12 8-13 14-15 14-16 15-17 15-18
ring bonds :
1-2 1-5 2-3 3-4 4-5
exact/norm bonds :
4-7 7-8 8-11 8-12 8-13 14-15 14-16 15-18
exact bonds :
1-2 1-5 2-3 3-4 3-14 4-5 15-17
isolated ring systems :
containing 1 :

G1:O,S,N,CH2

G2:CH2,NH

G3:Cb,Cy,Hy,Ak,Ph

Match level :
1:Atom 2:Atom 3:Atom 4:Atom 5:Atom 7:CLASS 8:CLASS 11:CLASS 12:CLASS
13:CLASS 14:CLASS 15:CLASS 16:CLASS 17:CLASS 18:CLASS

L6 STRUCTURE UPLOADED

=> d l6
L6 HAS NO ANSWERS
L6 STR



G1 O,S,N,CH2

G2 CH2,NH

G3 Cb,Cy,Hy,Ak,Ph

Structure attributes must be viewed using STN Express query preparation.

=> s l6
SAMPLE SEARCH INITIATED 09:55:42 FILE 'REGISTRY'
SAMPLE SCREEN SEARCH COMPLETED - 14 TO ITERATE

100.0% PROCESSED 14 ITERATIONS 6 ANSWERS
SEARCH TIME: 00.00.01

FULL FILE PROJECTIONS: ONLINE **COMPLETE**
BATCH **COMPLETE**
PROJECTED ITERATIONS: 56 TO 504
PROJECTED ANSWERS: 6 TO 266

L7 6 SEA SSS SAM L6

=> s l6 sss full
FULL SEARCH INITIATED 09:55:48 FILE 'REGISTRY'
FULL SCREEN SEARCH COMPLETED - 154 TO ITERATE

100.0% PROCESSED 154 ITERATIONS 36 ANSWERS
SEARCH TIME: 00.00.01

L8 36 SEA SSS FUL L6

=> FIL HCAPLUS

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	196.86	467.21

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	0.00	-6.96

FILE 'HCAPLUS' ENTERED AT 09:55:52 ON 22 FEB 2011
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.

FILE COVERS 1907 - 22 Feb 2011 VOL 154 ISS 9
FILE LAST UPDATED: 21 Feb 2011 (20110221/ED)
REVISED CLASS FIELDS (/NCL) LAST RELOADED: Oct 2010
USPTO MANUAL OF CLASSIFICATIONS THESAURUS ISSUE DATE: Oct 2010

HCAplus now includes complete International Patent Classification (IPC) reclassification data for the fourth quarter of 2010.

CAS Information Use Policies apply and are available at:

http://www.cas.org/legal/infopolicy.html

This file contains CAS Registry Numbers for easy and accurate substance identification.

```
=> s l8
L9            7 L8

=> s l9 and py<=2004
      25160617 PY<=2004
L10           3 L9 AND PY<=2004

=> d l10 ibib abs hitstr tot
```

L10 ANSWER 1 OF 3 HCAPLUS COPYRIGHT 2011 ACS on STN
ACCESSION NUMBER: 2001:876610 HCAPLUS
DOCUMENT NUMBER: 136:19953
TITLE: Preparation of alkynyl aryl sulfonamide hydroxamic acids as TNF-α converting enzyme inhibitors.
INVENTOR(S): Levin, Jeremy I.; Chen, James M.; Zask, Arie
PATENT ASSIGNEE(S): American Cyanamid Company, USA
SOURCE: U.S., 21 pp.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6326516	B1	20011204	US 2000-492980	20000127

<--
PRIORITY APPLN. INFO.: US 1999-155250P P 19990127

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
OTHER SOURCE(S): MARPAT 136:19953
AB R8C.tplbond.CCR6R7ZYXNR5CHR11CHR12CONHOH, R8C.tplbond.CCR6R7ZYXNR5CR11:CR12CONHOH [X = SO2, P(O)R10; Y = heteroaryl, Ph, naphthyl; Z = O, NH, CH2, S; R5 = H, alkyl; R6, R7 = H, Me; R8 = H, alkyl, alkenyl, alkynyl, cycloalkyl, heteroaryl, Ph, etc.; R10 = alkyl, cycloalkyl, Ph, heteroaryl; R11, R12 = H, alkyl, cycloalkyl, heteroaryl, Ph; R11R12 = atoms to form (fused) (unsatd.) ring; with provisos], were prepared Thus, (1R,2S)-2-[[[4-(2-butynyloxy)phenyl]sulfonyl](methyl)amino]-N-hydroxycyclopentanecarboxamide (general preparation given) inhibited TNF-α converting enzyme (TACE) with IC50 = 14 nM.
IT 287096-63-3P, (cis)-2-[[[4-(2-Butynyloxy)phenyl]sulfonyl]amino)-N-hydroxycyclohexanecarboxamide 376630-56-7P, (1R,2R)-2-[[[4-(2-Butynyloxy)phenyl]sulfonyl]amino]-N-hydroxycyclohexanecarboxamide 376630-57-8P, (1R,2S)-2-[[[4-(2-Butynyloxy)phenyl]sulfonyl]amino]-N-hydroxycyclopentanecarboxamide 376630-59-0P, (1R,2R,3S,4R)-3-([[4-(2-Butynyloxy)phenyl]sulfonyl]amino)-N-hydroxybicyclo[2.2.1]heptan-2-carboxamide
RL: PAC (Pharmacological activity); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of alkynyl aryl sulfonamide hydroxamic acids as TNF-α converting enzyme inhibitors)
RN 287096-63-3 HCAPLUS
CN Cyclohexanecarboxamide, 2-[[[4-(2-butyn-1-yloxy)phenyl]sulfonyl]amino]-N-hydroxy-, (1R,2S)-rel- (CA INDEX NAME)

Relative stereochemistry.

L10 ANSWER 1 OF 3 HCAPLUS COPYRIGHT 2011 ACS on STN (Continued)



OS.CITING REF COUNT: 7 THERE ARE 7 CAPLUS RECORDS THAT CITE THIS RECORD (7 CITINGS)
REFERENCE COUNT: 73 THERE ARE 73 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 1 OF 3 HCAPLUS COPYRIGHT 2011 ACS on STN (Continued)



RN 376630-56-7 HCAPLUS
CN Cyclohexanecarboxamide, 2-[[[4-(2-butyn-1-yloxy)phenyl]sulfonyl]amino]-N-hydroxy-, (1R,2R)- (CA INDEX NAME)

Absolute stereochemistry.



RN 376630-57-8 HCAPLUS
CN Cyclopentanecarboxamide, 2-[[[4-(2-butyn-1-yloxy)phenyl]sulfonyl]amino]-N-hydroxy-, (1R,2S)- (CA INDEX NAME)

Absolute stereochemistry.



RN 376630-59-0 HCAPLUS
CN Bicyclo[2.2.1]heptane-2-carboxamide, 3-[[[4-(2-butyn-1-yloxy)phenyl]sulfonyl]amino]-N-hydroxy-, (1R,2R,3S,4R)- (CA INDEX NAME)

Absolute stereochemistry.

L10 ANSWER 2 OF 3 HCAPLUS COPYRIGHT 2011 ACS on STN
ACCESSION NUMBER: 2000:553546 HCAPLUS
DOCUMENT NUMBER: 133:150358
TITLE: Preparation of sulfonamide derivatives having cyclic structures as matrix metalloprotease inhibitors and TNF production inhibitors
INVENTOR(S): Watanabe, Fumihiko; Tsuzuki, Hiroshige
PATENT ASSIGNEE(S): Shionogi and Co., Ltd., Japan
SOURCE: PCT Int. Appl., 87 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000046189	A1	20000810	WO 2000-JP446	20000128

<--
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG
PRIORITY APPLN. INFO.: JP 1999-25058 A 19990202

OTHER SOURCE(S): MARPAT 133:150358
GI



AB The title derivs. I [A is Q1, etc.; R1 is COOR6 or the like; R6 is hydrogen, alkyl; R2 is optionally substituted arylene or the like; R3 is CONH or the like; R4 is optionally substituted aryl or the like; R5 is hydrogen or the like; and m and n are each independently 0 or 1] are prepared The title compound II in vitro showed IC50 of 9.7 μM against MMP-8. Formulations are given.
IT 287395-23-7P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological

L10 ANSWER 2 OF 3 HCAPLUS COPYRIGHT 2011 ACS on STN (Continued)
study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(prepn. of sulfonamide derivs. having cyclic structures as matrix metalloprotease inhibitors and TNF prodn. inhibitors)
RN 287395-23-7 HCAPLUS
CN Bicyclo[2.2.1]hept-5-ene-2-carboxamide, 3-[[[5-[4-(dimethylamino)phenyl]-2-thienyl]sulfonyl]amino]-N-hydroxy-, (1S,2S,3S,4R)- (CA INDEX NAME)

Absolute stereochemistry.



OS.CITING REF COUNT: 5 THERE ARE 5 CAPLUS RECORDS THAT CITE THIS RECORD
(6 CITINGS)
REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L10 ANSWER 3 OF 3 HCAPLUS COPYRIGHT 2011 ACS on STN
ACCESSION NUMBER: 2000:535104 HCAPLUS
DOCUMENT NUMBER: 133:150361
TITLE: Preparation of alkynyloxyphenylsulfonylaminoalkylhydroxamic acids and related compounds as TNF-α converting enzyme (TACE) inhibitors.
INVENTOR(S): Levin, Jeremy Ian; Chen, James Ming; Zask, Arie
PATENT ASSIGNEE(S): American Cyanamid Company, USA
SOURCE: PCT Int. Appl., 58 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000044711	A1	20000803	WO 2000-US1865	20000127
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2356345	A1	20000803	CA 2000-2356345	20000127
EP 1147078	A1	20011024	EP 2000-904570	20000127
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
BR 2000007754	A	20011113	BR 2000-7754	20000127
HU 2002000605	A2	20020729	HU 2002-605	20000127
HU 2002000605	A3	20050530		
JP 2002535383	T	20021022	JP 2000-595968	20000127
NZ 512025	A	20030829	NZ 2000-512025	20000127
AU 769410	B2	20040129	AU 2000-26306	20000127
ZA 2001004508	A	20020902	ZA 2001-4508	20010531
NO 2001003639	A	20010724	NO 2001-3639	20010724
MX 2001007465	A	20011203	MX 2001-7465	20010724

PRIORITY APPLN. INFO.: US 1999-239083 A 19990127
WO 2000-US1865 W 20000127

L10 ANSWER 3 OF 3 HCAPLUS COPYRIGHT 2011 ACS on STN (Continued)
OTHER SOURCE(S): MARPAT 133:150361
GI



I

AB Title compds. (I; X = SO2, POR10; Y = 5-10 membered heteroaryl, Ph, naphthyl; Z = O, NH, CH2, S; R5 = H, alkyl; R6, R7 = H, Me; R8 = H, alkyl, alkenyl, alkynyl, cycloalkyl, heteroaryl, heterocycloalkyl, Ph; R9 = H, alkyl, cycloalkyl, Ph; R10 = alkyl, cycloalkyl, Ph, heteroaryl; R11, R12 = H, alkyl, cycloalkyl, heteroaryl, heterocycloalkyl; R11R12 = atoms to form 5-10 membered mono- or bicyclic (heterocyclic) ring, Ph, naphthyl; dotted line = optional double bond), were prepared Thus, (1R,2S)-2-[[[4-(2-butynyloxy)phenyl]sulfonyl]methylamino]-N-hydroxycyclopentanecarboxamide [preparation from cis-2-amino-1-cyclopentanecarboxylic acid and 4-(2-butynyloxy)phenylsulfonyl chloride given] inhibited TACE with IC50 = 14 nM.
IT 287096-58-6P 287096-61-1P 287096-63-3P
287096-65-5P
RL: BAC (Biological activity or effector, except adverse); BSU (Biological study, unclassified); SPN (Synthetic preparation); THU (Therapeutic use); BIOL (Biological study); PREP (Preparation); USES (Uses)
(preparation of alkynyloxyphenylsulfonylaminoalkylhydroxamic acids and related compds. as TNF-α converting enzyme inhibitors)
RN 287096-58-6 HCAPLUS
CN Cyclohexanecarboxamide, 2-[[[4-(2-butyn-1-yloxy)phenyl]sulfonyl]amino]-N-hydroxy-, (1R,2R)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 287096-61-1 HCAPLUS
CN Cyclopentanecarboxamide, 2-[[[4-(2-butyn-1-yloxy)phenyl]sulfonyl]amino]-N-hydroxy-, (1R,2S)-rel- (CA INDEX NAME)

L10 ANSWER 3 OF 3 HCAPLUS COPYRIGHT 2011 ACS on STN (Continued)
Relative stereochemistry.



RN 287096-63-3 HCAPLUS
CN Cyclohexanecarboxamide, 2-[[[4-(2-butyn-1-yloxy)phenyl]sulfonyl]amino]-N-hydroxy-, (1R,2S)-rel- (CA INDEX NAME)

Relative stereochemistry.



RN 287096-65-5 HCAPLUS
CN Bicyclo[2.2.1]heptane-2-carboxamide, 3-[[[4-(2-butyn-1-yloxy)phenyl]sulfonyl]amino]-N-hydroxy-, (1R,2S,3R,4S)-rel- (CA INDEX NAME)

Relative stereochemistry.



OS.CITING REF COUNT: 4 THERE ARE 4 CAPLUS RECORDS THAT CITE THIS RECORD
(4 CITINGS)
REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

=> d l9 ibib abs tot

L9 ANSWER 1 OF 7 HCAPLUS COPYRIGHT 2011 ACS on STN
ACCESSION NUMBER: 2008:1088521 HCAPLUS
DOCUMENT NUMBER: 149:513677
TITLE: Development of a Suitable Process for the Preparation of a TNF-α Converting Enzyme Inhibitor, WAY-281418
AUTHOR(S): Wang, Youchu; Papamichelakis, Maria; Chew, Warren; Sellstedt, John; Noureldin, Razzak; Tadayon, Sam; Daigneault, Sylvain
CORPORATE SOURCE: Chemical Development, Wyeth Research, Saint-Laurent, QC, H4R 1J6, Can.
SOURCE: Organic Process Research & Development (2008), 12(6), 1253-1260
CODEN: OPRDFK; ISSN: 1083-6160
PUBLISHER: American Chemical Society
DOCUMENT TYPE: Journal
LANGUAGE: English
OTHER SOURCE(S): CASREACT 149:513677
GI



I



II



III

AB A suitable process for the preparation of kilogram quantities of a TNF-α converting enzyme (TACE) inhibitor (WAY-281418) was developed using isatin as starting material and an efficient coupling step for the formation of sulfonamide I in a 15% overall yield. Process preparation of (+)-(1S,2R)-2-aminocyclopentane-1-carboxylic acid (II, (+)-cispentacin), a chiral component for WAY-281418, was successfully scaled up via an asym.

L9 ANSWER 1 OF 7 HCAPLUS COPYRIGHT 2011 ACS on STN (Continued)
hydrogenation reaction. Crystn. allowed the isolation of all intermediates and the final product III.
REFERENCE COUNT: 17 THERE ARE 17 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 2 OF 7 HCAPLUS COPYRIGHT 2011 ACS on STN
ACCESSION NUMBER: 2006:979177 HCAPLUS
DOCUMENT NUMBER: 145:356664
TITLE: Preparation of β-sulfonamide hydroxamic acid inhibitors of TACE/matrix metalloproteinase
INVENTOR(S): Levin, Jeremy I.; Li, Zhong; Diamantidis, George; Lovering, Frank E.; Wang, Weiheng; Condon, Jeffrey S.; Lin, Yang-I.; Skotnicki, Jerauld S.; Park, Kaapjoo
PATENT ASSIGNEE(S): Wyeth, John, and Brother Ltd., USA
SOURCE: U.S. Pat. Appl. Publ., 61pp.
CODEN: USXXCO
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 20060211730	A1	20060921	US 2006-377886	20060316
US 7595327	B2	20090929		
PRIORITY APPLN. INFO.:			US 2005-663785P P	20050321

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
OTHER SOURCE(S): CASREACT 145:356664; MARPAT 145:356664
GI



I

AB This invention provides compds. of formula I (wherein J = (un)substituted a monocyclic or bicyclic 5-8 membered cycloalkyl or heterocycloalkyl; R2 = H, (un)substituted C1-C6 alkyl, C2-C6 alkenyl or C2-C6 alkynyl; R3 = (un)substituted naphthyl or bicyclic heteroaryl; R4 and R5 = independently H, (un)substituted C1-C6 alkyl, C2-C6 alkenyl or C2-C6 alkynyl; R8 and R9 = independently H, OH, substituted amino, halo, C1-C6 alkyl, etc.; E = -C:C-, -C:N-, -N:C-, S or O; X = O, S(O)n, or substituted amino; n = 0-2) that are useful in treating diseases or disorders mediated by TNF-α, such as arthritis (rheumatoid arthritis (RA), juvenile RA, psoriatic arthritis, osteoarthritis etc.), tumor metastasis, tissue ulceration, abnormal wound healing, periodontal disease, bone disease, diabetes (insulin resistance) and HIV infection, ankylosing spondylitis, psoriasis, sepsis, multiple sclerosis, Crohn's disease, degenerative cartilage loss, asthma, idiopathic pulmonary fibrosis, vasculitis, systemic lupus erythematosus, irritable bowel syndrome, acute coronary syndrome, hepatitis C, cachexia, COPD, stroke or type 2 diabetes, and for alleviation of symptoms thereof. The invention further provides methods for use of the compds. Prepn. of I is exemplified. For example, II was prepd. by reacting 3-endo-aminobicyclo[2.2.1]hept-5-ene-2-endo-carboxylic acid with 4-(2-methylquinolin-4-ylmethoxy)benzenesulfonyl chloride hydrochloride and reacting the intermediate formed with hydroxylamine. In an assay involving cleavage of pro-TNF by TACE, II had an IC50 of 1.2 nM.

L9 ANSWER 2 OF 7 HCAPLUS COPYRIGHT 2011 ACS on STN (Continued)
OS.CITING REF COUNT: 2 THERE ARE 2 CAPLUS RECORDS THAT CITE THIS RECORD (2 CITINGS)

L9 ANSWER 3 OF 7 HCAPLUS COPYRIGHT 2011 ACS on STN
ACCESSION NUMBER: 2006:757211 HCAPLUS
DOCUMENT NUMBER: 145:241166
TITLE: Targeting ADAM-mediated ligand cleavage to inhibit HER3 and EGFR pathways in non-small cell lung cancer
AUTHOR(S): Zhou, Bin-Bing S.; Peyton, Michael; He, Biao; Liu, Changnian; Girard, Luc; Caudler, Eian; Lo, Yvonne; Baribaud, Frederic; Mikami, Iwao; Reguart, Noemi; Yang, Gengjie; Li, Yanlong; Yao, Wenqing; Vaddi, Kris; Gazdar, Adi F.; Friedman, Steven M.; Jablons, David M.; Newton, Robert C.; Fridman, Jordan S.; Minna, John D.; Scherle, Peggy A.
CORPORATE SOURCE: Drug Discovery, Experimental Station, Incyte Corporation, Wilmington, DE, 19880, USA
SOURCE: Cancer Cell (2006), 10(1), 39-50
CODEN: CCAECI; ISSN: 1535-6108
PUBLISHER: Cell Press
DOCUMENT TYPE: Journal
LANGUAGE: English

AB We describe here the existence of a heregulin-HER3 autocrine loop, and the contribution of heregulin-dependent, HER2-mediated HER3 activation to gefitinib insensitivity in non-small cell lung cancer (NSCLC). ADAM17 protein, a major ErbB ligand sheddase, is upregulated in NSCLC and is required not only for heregulin-dependent HER3 signaling, but also for EGFR ligand-dependent signaling in NSCLC cell lines. A selective ADAM inhibitor, INCB3619, prevents the processing and activation of multiple ErbB ligands, including heregulin. In addition, INCB3619 inhibits gefitinib-resistant HER3 signaling and enhances gefitinib inhibition of EGFR signaling in NSCLC. These results show that ADAM inhibition affects multiple ErbB pathways in NSCLC and thus offers an excellent opportunity for pharmacol. intervention, either alone or in combination with other drugs.

OS.CITING REF COUNT: 98 THERE ARE 98 CAPLUS RECORDS THAT CITE THIS RECORD (99 CITINGS)
REFERENCE COUNT: 60 THERE ARE 60 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 4 OF 7 HCAPLUS COPYRIGHT 2011 ACS on STN
ACCESSION NUMBER: 2005:1075765 HCAPLUS
DOCUMENT NUMBER: 143:346847
TITLE: Preparation of cyclohexylcarboxamide derivatives as inhibitors of matrix metalloproteinases
INVENTOR(S): Ananthan, Subramaniam
PATENT ASSIGNEE(S): Southern Research Institute, USA
SOURCE: PCT Int. Appl., 52 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2005092844	A1	20051006	WO 2005-US9263	20050321
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NA, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SM, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: BW, GH, GM, KE, LS, MW, MZ, NA, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
AU 2005227311	A1	20051006	AU 2005-227311	20050321
CA 2560739	A1	20051006	CA 2005-2560739	20050321
EP 1735274	A1	20061227	EP 2005-729212	20050321
EP 1735274	B1	20091125		
R: AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IS, IT, LI, LT, LU, MC, NL, PL, PT, RO, SE, SI, SK, TR				
CN 101001834	A	20070718	CN 2005-80016346	20050321
JP 2007530546	T	20071101	JP 2007-505043	20050321
NZ 550621	A	20091127	NZ 2005-550621	20050321
PT 1735274	E	20091211	PT 2005-729212	20050321
AT 449760	T	20091215	AT 2005-729212	20050321
ES 2338243	T3	20100505	ES 2005-729212	20050321
MX 2006010974	A	20070423	MX 2006-10974	20060922
IN 2006DN05647	A	20070831	IN 2006-DN5647	20060928
KR 2007046025	A	20070502	KR 2006-7021920	20061023
US 20080312329	A1	20081218	US 2008-593748	20080728

PRIORITY APPLN. INFO.: US 2004-555380P P 20040322
WO 2005-US9263 W 20050321

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
OTHER SOURCE(S): CASREACT 143:346847; MARPAT 143:346847
GI

L9 ANSWER 4 OF 7 HCAPLUS COPYRIGHT 2011 ACS on STN (Continued)



I



II

AB Title compds. I [X = (CH2)nO, (CH2)nS, (CH2)n(CH2), etc.; n = 0-2; R = (un)substituted alkyl, alkenyl, alkynyl, etc.; Z = NH or CH2] and their pharmaceutically acceptable salts, are prepared and disclosed as inhibitors of matrix metalloproteinases (MMP). Thus, e.g., II was prepared by sulfonylation of cis-2-amino-1-cyclohexanecarboxylic acid with biphenyl-4-sulfonyl chloride and subsequent amidation using O-(trimethylsilyl)hydroxylamine. The inhibitory activity of I towards MMP-2, MMP-3 and MMP-9 was evaluated using fluorometric substrate-degradation assays and it was revealed that selected compds. of the invention displayed IC50 values in the range of 125 up to 150 nM against MMP-2, 145 up to 175 nM against MMP-9 and above 3000 nM against MMP-3. I as inhibitors of matrix metalloproteinases should prove useful in the treatment of leukemia, melanoma and carcinoma. Pharmaceutical compns. comprising I are disclosed.

OS.CITING REF COUNT: 2 THERE ARE 2 CAPLUS RECORDS THAT CITE THIS RECORD (2 CITINGS)
REFERENCE COUNT: 3 THERE ARE 3 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 5 OF 7 HCAPLUS COPYRIGHT 2011 ACS on STN
ACCESSION NUMBER: 2001:876610 HCAPLUS
DOCUMENT NUMBER: 136:19953
TITLE: Preparation of alkynyl aryl sulfonamide hydroxamic acids as TNF-α converting enzyme inhibitors.
INVENTOR(S): Levin, Jeremy I.; Chen, James M.; Zask, Arie
PATENT ASSIGNEE(S): American Cyanamid Company, USA
SOURCE: U.S., 21 pp.
CODEN: USXXAM
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
US 6326516	B1	20011204	US 2000-492980	20000127

PRIORITY APPLN. INFO.: US 1999-155250P P 19990127

ASSIGNMENT HISTORY FOR US PATENT AVAILABLE IN LSUS DISPLAY FORMAT
OTHER SOURCE(S): MARPAT 136:19953

AB R8C.tplbond.CCR6R7ZYXNR5CHR11CHR12CONHOH, R8C.tplbond.CCR6R7ZYXNR5CR11:CR12CONHOH [X = SO2, P(O)R10; Y = heteroaryl, Ph, naphthyl; Z = O, NH, CH2, S; R5 = H, alkyl; R6, R7 = H, Me; R8 = H, alkyl, alkenyl, alkynyl, cycloalkyl, heteroaryl, Ph, etc.; R10 = alkyl, cycloalkyl, Ph, heteroaryl; R11, R12 = H, alkyl, cycloalkyl, heteroaryl, Ph; R11R12 = atoms to form (fused) (unsatd.) ring; with provisos], were prepared Thus, (1R,2S)-2-[[[4-(2-butynyloxy)phenyl]sulfonyl](methyl)amino]-N-hydroxycyclopentanecarboxamide (general preparation given) inhibited TNF-α converting enzyme (TACE) with IC50 = 14 nM.

OS.CITING REF COUNT: 7 THERE ARE 7 CAPLUS RECORDS THAT CITE THIS RECORD (7 CITINGS)
REFERENCE COUNT: 73 THERE ARE 73 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 6 OF 7 HCAPLUS COPYRIGHT 2011 ACS on STN
ACCESSION NUMBER: 2000:553546 HCAPLUS
DOCUMENT NUMBER: 133:150358
TITLE: Preparation of sulfonamide derivatives having cyclic structures as matrix metalloprotease inhibitors and TNF production inhibitors
INVENTOR(S): Watanabe, Fumihiko; Tsuzuki, Hiroshige
PATENT ASSIGNEE(S): Shionogi and Co., Ltd., Japan
SOURCE: PCT Int. Appl., 87 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: Japanese
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000046189	A1	20000810	WO 2000-JP446	20000128
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
PRIORITY APPLN. INFO.:			JP 1999-25058	A 19990202

OTHER SOURCE(S): MARPAT 133:150358
GI



I

II

AB The title derivs. I [A is Q1, etc.; R1 is COOR6 or the like; R6 is hydrogen, alkyl; R2 is optionally substituted arylene or the like; R3 is CONH or the like; R4 is optionally substituted aryl or the like; R5 is hydrogen or the like; and m and n are each independently 0 or 1] are prepared. The title compound II in vitro showed IC50 of 9.7 μM against MMP-8. Formulations are given.
OS.CITING REF COUNT: 5 THERE ARE 5 CAPLUS RECORDS THAT CITE THIS RECORD

L9 ANSWER 6 OF 7 HCAPLUS COPYRIGHT 2011 ACS on STN (Continued)
(6 CITINGS)
REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L9 ANSWER 7 OF 7 HCAPLUS COPYRIGHT 2011 ACS on STN
ACCESSION NUMBER: 2000:535104 HCAPLUS
DOCUMENT NUMBER: 133:150361
TITLE: Preparation of alkynyloxyphenylsulfonylaminoalkylhydroxamic acids and related compounds as TNF-α converting enzyme (TACE) inhibitors.
INVENTOR(S): Levin, Jeremy Ian; Chen, James Ming; Zask, Arie
PATENT ASSIGNEE(S): American Cyanamid Company, USA
SOURCE: PCT Int. Appl., 58 pp.
CODEN: PIXXD2
DOCUMENT TYPE: Patent
LANGUAGE: English
FAMILY ACC. NUM. COUNT: 1
PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000044711	A1	20000803	WO 2000-US1865	20000127
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CR, CU, CZ, DE, DK, DM, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, TZ, UA, UG, UZ, VN, YU, ZA, ZW				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
CA 2356345	A1	20000803	CA 2000-2356345	20000127
EP 1147078	A1	20011024	EP 2000-904570	20000127
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
BR 2000007754	A	20011113	BR 2000-7754	20000127
HU 2002000605	A2	20020729	HU 2002-605	20000127
HU 2002000605	A3	20050530		
JP 2002535383	T	20021022	JP 2000-595968	20000127
NZ 512025	A	20030829	NZ 2000-512025	20000127
AU 769410	B2	20040129	AU 2000-26306	20000127
ZA 2001004508	A	20020902	ZA 2001-4508	20010531
NO 2001003639	A	20010724	NO 2001-3639	20010724
MX 2001007465	A	20011203	MX 2001-7465	20010724
PRIORITY APPLN. INFO.:			US 1999-239083	A 19990127
			WO 2000-US1865	W 20000127

OTHER SOURCE(S): MARPAT 133:150361
GI



I

L9 ANSWER 7 OF 7 HCAPLUS COPYRIGHT 2011 ACS on STN (Continued)
AB Title compds. (I; X = SO2, POR10; Y = 5-10 membered heteroaryl, Ph, naphthyl; Z = O, NH, CH2, S; R5 = H, alkyl; R6, R7 = H, Me; R8 = H, alkyl, alkenyl, alkynyl, cycloalkyl, heteroaryl, heterocycloalkyl, Ph; R9 = H, alkyl, cycloalkyl, Ph; R10 = alkyl, cycloalkyl, Ph, heteroaryl; R11, R12 = H, alkyl, cycloalkyl, heteroaryl, heterocycloalkyl; R11R12 = atoms to form 5-10 membered mono- or bicyclic (heterocyclic) ring, Ph, naphthyl; dotted line = optional double bond), were prepared Thus, (1R,2S)-2-[[[4-(2-butynyloxy)phenyl]sulfonyl]methylamino]-N-hydroxycyclopentanecarboxamide [preparation from cis-2-amino-1-cyclopentanecarboxylic acid and 4-(2-butynyloxy)phenylsulfonyl chloride given] inhibited TACE with IC50 = 14 nM.
OS.CITING REF COUNT: 4 THERE ARE 4 CAPLUS RECORDS THAT CITE THIS RECORD
(4 CITINGS)
REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

```
=> log y
COST IN U.S. DOLLARS                                SINCE FILE      TOTAL
                                                      ENTRY    SESSION
FULL ESTIMATED COST                                    52.24     519.45

DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)          SINCE FILE      TOTAL
                                                      ENTRY    SESSION
CA SUBSCRIBER PRICE                                    -8.70     -15.66

STN INTERNATIONAL LOGOFF AT 09:58:14 ON 22 FEB 2011
```